Method for enriching tumor-infiltrating lymphocytes

By using polymer matrix and IL-2 regulation of anti-CD3 and anti-CD28 antibodies during TIL amplification, the time-consuming and labor-intensive problem of existing TIL amplification methods is solved, and efficient and simple TIL production is achieved. The generated TIL is equipped with Higher clinical efficacy.

CN118973590APending Publication Date: 2024-11-15CIBMAN BIOTECHNOLOGY GRP
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202380019215.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-08
Filing Date
2023-01-27
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing TIL amplification methods are time-consuming, cumbersome and expensive, and the TIL produced in conventional protocols is mainly terminal differentiation phenotypes related to poor clinical efficacy, lacking an easier and GMP-compliant method to replace the standard protocol, generating TIL with a favorable phenotype.

Method used

A first cell population is cultured in the first cell culture medium and contacted with a polymer matrix containing anti-CD3 antibodies and anti-CD28 antibodies or fragments thereof in the second cell culture medium to generate a third cell population by adjustment IL-2 concentration and incubation time promote the amplification and enrichment of TIL, and generate TIL with high CD8/CD4 ratio and memory enhancement.

Benefits of technology

The rapid amplification and efficient TIL production was achieved, and the relatively high CD8/CD4 ratio and low surface level of exhaustion markers were maintained. The generated TIL was more effective for cancer immunotherapy, and the process was simpler and GMP standards were met.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004967078040000594
    Figure BDA0004967078040000594
  • Figure BDA0004967078040000601
    Figure BDA0004967078040000601
  • Figure BDA0004967078040000602
    Figure BDA0004967078040000602
Patent Text Reader

Abstract

The present disclosure provides improved methods of amplifying tumor-infiltrating lymphocytes (TILs) and generating therapeutic TIL populations for shorter periods of time than conventional methods. TIL cell therapy products that easily conform to target cell doses while maintaining desired T cell phenotypes can be manufactured.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application Nos. 63 / 304,288 (filed on January 28, 2022), 63 / 411,317 (filed on September 29, 2022), and 63 / 423,676 (filed on November 8, 2022), each of which is incorporated herein by reference in its entirety. Background Art

[0003] Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) offers a potential treatment option for cancer. TILs are enriched with polyclonal T cells with diverse antigen specificities. Extraction of tumor fragments followed by ex vivo expansion removes TILs from the hostile tumor microenvironment and reduces the immunosuppressive effects of intratumoral regulatory T cells. Ex vivo expansion of TILs rejuvenates the cells, producing billions of cells to be infused back into the patient. Cell therapy products that can address a wide range of tumor neoantigens and a unique array of tumor neoantigens from each patient will result in a potentially tailored response. Samaik et al., J. Clinical Oncology, 2021, 39: 2656-2666.

[0004] Effective treatment of cancer with TILs requires the ex vivo generation of billions of TILs. To make TILs, the resected patient tumor is first fragmented and cultured in vitro under conditions that support TIL migration from the tumor tissue. In conventional protocols, the number of TILs is then expanded using a rapid expansion protocol (REP) using irradiated allogeneic donor peripheral blood mononuclear cells (PBMCs) and anti-CD3 monoclonal antibodies. REP is used to generate enough TILs for infusion. Several factors, including the availability and validation of donor PBMCs, make conventional REP protocols time-consuming, cumbersome, and expensive. In addition to these derogatory factors, TIL expansion using standard protocols also primarily shows a terminally differentiated phenotype (T EM , T EMRA Young memory phenotype in TIL infusion products (T SCM , T CM ) have been associated with improved anti-tumor responses in patients. Therefore, there is a need to replace the conventional REP protocol with an easier yet GMP-compliant approach that can generate TILs with a favorable phenotype while using readily available commercial reagents. Summary of the invention

[0005] The present disclosure provides a method for expanding tumor infiltrating lymphocytes (TILs), the method comprising: (a) culturing a first cell population in a first cell culture medium to generate a second cell population; and (b) contacting the second cell population with a polymer matrix comprising an anti-CD3 antibody and an anti-CD28 antibody or a fragment thereof in the second cell culture medium to generate a third cell population. In certain embodiments, the first cell population is obtained from a tumor sample of a patient.

[0006] The third cell population can be a TIL or cell to be included in the pharmaceutical composition of the present invention. The third cell population can be a TIL or cell to be used in the method of the present invention to treat a subject (e.g., patient) with cancer.

[0007] In certain embodiments, the second cell culture medium comprises about 100 IU / mL to about 8000 IU / mL interleukin-2 (IL-2), about 500 IU / mL to about 4000 IU / mL IL-2, about 1000 IU / mL, about 2000 IU / mL, about 3000 IU / mL, about 4000 IU / mL, or about 5000 IU / mL IL-2.

[0008] In certain embodiments, the first cell culture medium comprises about 2000 IU / mL to about 8000 IU / mL IL-2, about 5000 IU / mL, about 6000 IU / mL, about 7000 IU / mL, or about 8000 IU / mL IL-2.

[0009] In certain embodiments, the first cell population is cultured in step (a) for about 10 days to about 40 days, about 10 days to about 14 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, or about 17 days.

[0010] The method may further comprise cryopreserving the second cell population after step (a).

[0011] In certain embodiments, the contacting in step (b) is about 3 days to about 17 days, about 5 days to about 15 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, or about 17 days.

[0012] In certain embodiments, the third population of cells is at least 100 times greater in number than the second population of cells, or about 100 times to about 2000 times greater in number than the second population of cells.

[0013] Tumor samples can be from solid tumors. Solid tumors include, but are not limited to, sarcomas, hepatocellular carcinomas, gliomas, head and neck cancers, bone cancers, brain cancers, breast cancers, anal cancers, anal canal cancers, anorectal cancers, eye cancers, intrahepatic bile duct cancers, joint cancers, cervical cancers, pleural cancers, nasal cancers, nasal cavity cancers, middle ear cancers, oral cancers, vulvar cancers, colon cancers, esophageal cancers, cervical cancers, gastrointestinal cancers, hypopharyngeal cancers, laryngeal cancers, liver cancers, lung cancers, malignant mesothelioma, melanomas, nasopharyngeal cancers, ovarian cancers, pancreatic cancers, peritoneal cancers, omental cancers, mesenteric cancers, pharyngeal cancers, prostate cancers, rectal cancers, kidney cancers, small intestine cancers, soft tissue cancers, stomach cancers, testicular cancers, thyroid cancers, ureteral cancers, bladder cancers, and combinations thereof.

[0014] The present disclosure provides tumor infiltrating lymphocytes obtained by the method of the present invention.

[0015] The present disclosure also encompasses a cell population enriched for or expanded from tumor infiltrating lymphocytes, the cell population comprising one or more of the following:

[0016] (i) Percentage of CD3 + About 3% to about 88% of cells are CD3 + CD8 + T cells,

[0017] (ii) Percentage of CD3 + About 10% to about 96% of cells are CD3 + CD4 + T cells,

[0018] (iii) Percentage of CD4 + Cells from about 50% to about 88% CD4 + T CM T cells,

[0019] (iv) Percentage of CD8 + Cells from about 28% to about 82% CD8 + T CM T cells,

[0020] (v) Percentage of CD4 + Cells from about 11% to about 49% CD4 + T EM T cells, and

[0021] (vi) Percentage of CD8 + Cells from about 11% to about 61% CD8 + T EM T cells, wherein the cell population comprises no less than 70% viable cells, and wherein the cell population is generated from a tumor sample from a patient.

[0022] The cell population may contain no less than 80% CD3 + T cells.

[0023] The cell population can contain a percentage of CD4 + Cells from about 10% to about 51% CD4 + CD27 + T cells.

[0024] The cell population can contain a percentage of CD8 + Cells from about 12% to about 72% CD8 + CD27 + T cells.

[0025] The cell population can contain a percentage of CD8 + Cells are approximately 34% to approximately 95% CD8 + CD28 + T cells.

[0026] The cell population can contain a percentage of CD4 + Cells from about 82% to about 100% CD4 + CD28 + T cells.

[0027] The cell population can contain a percentage of CD4 + About 0.2% to about 5.8% of cells are CD4 + 4-1BB + T cells.

[0028] The cell population can contain a percentage of CD8 + About 0.2% to about 11.6% of cells are CD8 + 4-1BB + T cells.

[0029] The cell population can contain a percentage of CD4 + Cells from about 0.2% to about 19.5% CD4 + LAG3 + T cells.

[0030] The cell population can contain a percentage of CD8 + Cells from about 6% to about 51.2% CD8 + LAG3 + T cells.

[0031] The cell population can contain a percentage of CD4 + Cells from about 0.9% to about 31% CD4 + PD1 + T cells.

[0032] The cell population can contain a percentage of CD8 + About 1% to about 18% of cells are CD8 + PD1 + T cells.

[0033] The cell population may contain no more than 10% CD56 + NK cells.

[0034] The present disclosure provides cell populations obtained by the methods of the present invention.

[0035] The method may include: (a) culturing a first cell population in a first cell culture medium to generate a second cell population; and (b) contacting the second cell population with a polymer matrix comprising an anti-CD3 antibody and an anti-CD28 antibody or a fragment thereof in the second cell culture medium to generate a third cell population. In certain embodiments, the first cell population is obtained from a tumor sample of a patient. The third cell population may be a cell population generated by the method of the present invention.

[0036] The present disclosure provides a method for expanding a cell population enriched for tumor-infiltrating lymphocytes. The method may include: (a) culturing cells obtained from a tumor sample of a patient; (b) treating the cultured cells to generate a cell population enriched for tumor-infiltrating lymphocytes, wherein the cell population comprises one or more of the following:

[0037] (i) Percentage of CD3 + About 3% to about 88% of cells are CD3 + CD8 + T cells,

[0038] (ii) Percentage of CD3 + About 10% to about 96% of cells are CD3 + CD4 + T cells,

[0039] (iii) Percentage of CD4 + Cells from about 50% to about 88% CD4 + CD45RA - CD62L + Central memory T cells,

[0040] (iv) Percentage of CD8 + Cells from about 28% to about 82% CD8 + CD45RA - CD62L + Central memory T cells,

[0041] (v) Percentage of CD4 +Cells from about 11% to about 49% CD4 + CD45RA-CD62L- effector memory T cells, and

[0042] (vi) Percentage of CD8 + Cells from about 11% to about 61% CD8 + T CD45RA-CD62L- effector memory T cells.

[0043] The present disclosure also encompasses a method of treating a cancer patient comprising administering to the patient a tumor infiltrating lymphocyte of the invention, a cell population of the invention, a cell of the invention (eg, a third cell population), or a composition of the invention.

[0044] The present disclosure provides a pharmaceutical composition comprising the tumor infiltrating lymphocytes of the present invention, the cell population of the present invention, or the cells of the present invention (eg, the third cell population).

[0045] In certain embodiments, about 1×10 9 to about 1×10 11 cells or about 5×10 9 About 9×10 10 cells.

[0046] Cancer can be melanoma, cervical cancer, lung cancer, colorectal cancer, breast cancer or head and neck cancer.Cancer can include sarcoma, hepatocellular carcinoma, glioma, head and neck cancer, bone cancer, brain cancer, breast cancer, anal cancer, anorectal cancer, eye cancer, intrahepatic bile duct cancer, joint cancer, cervical cancer, gallbladder cancer, pleural cancer, nasal cancer, nasal cavity cancer, middle ear cancer, oral cancer, vulvar cancer, colon cancer, esophageal cancer, cervical cancer, gastrointestinal cancer, hypopharyngeal cancer, laryngeal cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, peritoneal cancer, omental cancer, mesenteric cancer, pharyngeal cancer, prostate cancer, rectal cancer, kidney cancer, small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, ureter cancer, bladder cancer or a combination thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1 Figure 2: TIL expansion and glucose / lactate levels in REP TIL cultures following a standardized protocol. In the standardized REP protocol, tumor fragments were placed in a G-1 medium containing 250 mL of REP complete medium. In the 100M device, 1 volume of medium was fed on day 10 and harvested on day 14. Supernatants were sampled on days 0, 6, 10, and 14.

[0048] Figure 2 : Lineage characterization of prepared REP TILs from a standardized protocol. CD45+ NK and CD45 in cells + CD3-CD56 + ;CD45 + B and CD45 in cells + CD3-CD19 + ;CD45 + Myeloid cells, CD45 + CD3-CD14 + ; Epithelial, CD45-EPCAM in living cells + ;CD45 + CD3 in cells + T cells; CD3 + CD4 in T cells + T and CD8 + T.

[0049] Figure 3 : CD4 generated following a standardized protocol + Activation / inhibitory surface marker expression and subsets of REP TILs.

[0050] Figure 4 : CD8 generated following a standardized protocol + Activation / inhibitory surface marker expression and subsets of REP TILs.

[0051] Figure 5 : CD3 in TILs expanded by conventional REP or TransAct REP + T cells and CD4 + and percentages of CD8+ T cell subsets. Statistical significance was determined by paired t-test: **P<0.01; ns: not significant (n=12).

[0052] Figure 6 : CD4 + TIL and CD8 + Memory phenotype of TILs. Top panel: CD4, bottom panel: CD8. Each dot represents a donor. Horizontal scale represents mean and standard deviation. N , naive T cells; T SCM , stem cell memory T cells; T CM , central memory T cells; T EM , effector memory T cells; T EFF , effector T cells. P values ​​were generated by Student's paired t test. Ns: not significant; *P<0.05; **P<0.01; *** p <0.001; ****P<0.0001 (n=12).

[0053] Figure 7 : Analysis of CD4 + and CD8 + Inhibitory and activation markers on TIL subsets. Top panel: CD4, bottom panel: CD8. Each dot represents one donor. Horizontal scale represents mean and standard deviation. P values ​​were generated by Studen paired t test. ns: not significant; *P<0.05; **P<0.01; ***p<0.001 (n=12).

[0054] Figure 8 : IFN-γ and granzyme B production in response to αCD3 stimulation. All donors were stimulated in triplicate and each dot represents their mean. The horizontal scale represents the grand mean of different donors in each condition. P values ​​were generated by paired t-test. ns: not significant; *P<0.05; **P<0.01.

[0055] Fig. 9 : Tumor killing effect of C-TIL051 (TransAct REP TIL) and conventional REP TIL during incubation with autologous tumor cells. TIL from donor T5101016 was labeled with Cytolight Rapid Red and then co-cultured with cancer MOS at E:T ratios of 2:1, 3:1 and 4:1 in medium containing Caspase 3 / 7 Green for 68 hours. MOS alone served as a negative control. Higher caspase 3 / 7 signals indicate more killing.

[0056] Fig.10 : Use TransAct and The dynamic changes of IL-2 protein concentration in C-TIL051REP PD running culture during device. The IL-2 protein concentration in the culture supernatant samples collected at REP CM (day 0) or multiple time points was measured by ELISA (left). The samples from 7 REP runs were analyzed, and the TILs of different donors showed different amplification levels (right; the 14th day data represent the predicted numbers (projected number) after considering the corresponding flask coefficients at day 9).

[0057] Fig.11 : Use TransAct and The dynamic changes of glucose level and lactate level in C-TIL051REP PD operation culture during device. Glucose concentration and lactate concentration in culture supernatant samples collected at REPCM (day 0) or multiple time points were measured by Glucose-Glo assay and Lactate-Glo assay, respectively. Samples from 7 REP runs were analyzed, in which TILs from different donors showed different amplification levels.

[0058] Fig.12 : In use Device uses TransAct to perform post-REP CD4 + TIL and CD8 + FACS analysis of surface marker expression and memory phenotype of TILs. Data are shown as means with 95% CI. N (Tnaive), naive T cells; T SCM (Tscm), stem memory T cells; T CM (Tcm), central memory T cells; T EM (Tem), effector memory T cells; T EFF , effector T cells.

[0059] Fig.13 : With TransAct and in sequence Installation and Xuri TM Dynamic changes in IL-2 protein concentration in C-TIL051REP PD run cultures in the W25 bioreactor. After sampling the culture supernatant, the culture was inoculated into Xuri on the same day. TM Cellbag was then sampled daily from day 8 until harvest.

[0060] Fig.14 : With TransAct and in sequence Installation and Xuri TM Dynamic changes in glucose and lactate concentrations in C-TIL051REP PD run cultures in the W25 bioreactor. After sampling the culture supernatant, the culture was inoculated into Xuri on the same day. TM Cellbag was then sampled daily from day 8 until harvest.

[0061] Fig.15 : With TransAct and in sequence Installation and Xuri TMCell proliferation, viability, and cumulative expansion fold of REP TIL from C-TIL051PD run in W25 bioreactor. Five preparatory REP samples were first activated with TransAct and 100M device and then transferred to Xuri on day 7 TM W25 bioreactor. TM The cells were further expanded for 8-12 days with daily sampling for cell proliferation and viability testing.

[0062] Fig.16 : With the help of TransAct and in turn using Installation and Xuri TM CD4 after REP in W25 bioreactor + TIL and CD8 + FACS analysis of surface marker expression and memory phenotype of TILs. Data are shown as means with 95% CI. N , naive T cells; T SCM , stem memory T cells; T CM , central memory T cells; T EM , effector memory T cells; T EFF , effector T cells.

[0063] Fig.17 : IFN-γ production by C-TIL051 from Mock Runs in response to αCD3 / CD28 stimulation.

[0064] Fig.18 : Upregulation of T cell activation markers (4-1BB and OX40) by C-TIL051 Engineer Runs in response to αCD3 stimulation. Horizontal lines indicate the overall mean.

[0065] Fig.19 : Evaluation of C-TIL051-mediated MOS killing using a T cell efficacy assay. Quantification of relative T5101034 (left) and T5101035 (right) autologous TIL-induced MOS killing observed at E:T ratios of 1:1, 5:1, and 10:1. Co-culture was initiated on day 3 after establishment of MOS, and images were acquired for up to 96 h. Mean integrated fluorescence intensity of the NIR channel (NIRCU×μm 2 ) From live tumor cells labeled with NIR680 dye. Data were normalized to the MOS-only group.

[0066] Fig. 20: Requirement for HLA engagement shows specificity of C-TIL051-mediated MOS killing. Co-culture of C-TIL051REP TILs with autologous MOS was performed with or without the indicated HLA blocking antibodies at an effector cell:target cell ratio of 5:1 and analyzed for up to 96 h. Mean integrated fluorescence intensity of the NIR channel (NIRCU × μm 2 ) From live tumor cells labeled with NIR680 dye. Data shown are normalized to the MOS-only group.

[0067] Fig.21 : HLA class I and II blockade reduces cytokine production in co-cultures of C-TIL051 and autologous MOS.

[0068] C-TIL051: TIL generated by an embodiment of the method of the present invention. DETAILED DESCRIPTION

[0069] The present disclosure provides a method for amplifying tumor infiltrating lymphocytes (TIL). The method of the present invention does not require the use of feeder cells such as PBMC. Compared with TIL generated / amplified using irradiated PBMC, TIL generated / amplified using the method of the present invention is associated with preferential CD8TIL amplification and keeps the surface level of exhaustion markers (such as PD-1) on TIL low. Specifically, TIL generated / amplified using the method of the present invention: (1) maintains a relatively high CD8 / CD4 ratio; (2) has a higher percentage of Tnaive / scm and Tcm among CD4 and CD8T cells; and (3) shows a reduced PD-1 positive rate on CD4 and CD8T cells. The method of the present invention can rapidly amplify TIL with a high CD8 / CD4 ratio, and can generate TIL with a higher CD8 cytotoxic T cell ratio, reduced exhaustion and enhanced memory. Therefore, TIL generated by the method of the present invention is more effective for cancer immunotherapy.

[0070] The present disclosure also encompasses an autologous TIL therapy using a centralized production process, which uses tumor tissue T cells that are able to recognize tumor antigens and are expanded ex vivo while maintaining a heterogeneous T cell pool.

[0071] In certain embodiments, the cells of the present invention contain autologous TIL harvested from a patient's tumor sample. Tumor fragmentation can be first made and cultured under high doses of IL-2 to promote TIL to leave and amplify. The initial stage of this proliferation of TIL from tumor tissue is called the pre-rapid expansion scheme (preparatory REP (pre-REP)). After this initial in vitro culture, TIL can be further amplified with a rapid expansion scheme (REP) to achieve a therapeutic dose.

[0072] The present disclosure provides a method for expanding tumor infiltrating lymphocytes (TILs). The method may include: (a) culturing a first cell population in a first cell culture medium to generate a second cell population, wherein the first cell population is obtained from a tumor sample of a patient; and (b) contacting the second cell population with a polymer matrix containing anti-CD3 antibodies and anti-CD28 antibodies or fragments thereof in the second cell culture medium to generate a third cell population, wherein the second cell culture medium contains about 100 IU / mL to about 8000 IU / mL interleukin-2 (IL-2).

[0073] The method may further comprise cryopreserving a second cell population after the first expansion (preparatory REP, or step (a) of the method of the invention). The cryopreserved second cell population may then be thawed and subjected to a second expansion (REP, or step (b) of the method of the invention, e.g., contacted with a polymer matrix comprising an anti-CD3 antibody and an anti-CD28 antibody or a fragment thereof in a second cell culture medium). The second cell population may undergo a second expansion (REP, or step (b) of the method of the invention) immediately after thawing. The second cell population may undergo a second expansion (REP, or step (b) of the method of the invention) less than 2 days, less than 48 hours, less than 40 hours, less than 36 hours, less than 30 hours, less than 24 hours, less than 20 hours, less than 15 hours, less than 12 hours, less than 10 hours, less than 9 hours, less than 8 hours, less than 7 hours, less than 6 hours, less than 5 hours, less than 4 hours, less than 3 hours, less than 2 hours, or less than 1 hour after being recovered.

[0074] The second cell population (which includes the preparation REP TIL) can be cryopreserved until the patient's disease progresses. After the patient progresses, the preparation REP TIL is thawed and expanded according to the rapid expansion protocol (REP).

[0075] For frozen and thawed cell products, after standing overnight, the thawed cells can be contacted with a polymer matrix comprising anti-CD3 antibodies and anti-CD28 antibodies or fragments thereof, or can be activated. Alternatively, immediately and without standing overnight, the thawed cells can be contacted with a polymer matrix comprising anti-CD3 antibodies and anti-CD28 antibodies or fragments thereof, or can be activated. In one embodiment, the frozen cells are rapidly thawed at 37° C. in a water bath.

[0076] The volume ratio of TransAct to the second cell culture medium (or cell culture medium for second expansion, or REP cell culture medium) can range from about 1:200 to about 1:2, about 1:180 to about 1:2, about 1:150 to about 1:5, about 1:120 to about 1:5, about 1:100 to about 1:8, about 1:80 to about 1:8, about 1:50 to about 1:10, about 1:40 to about 1:10, about 1:30 to about 1:10, about 1:20 to about 1:10, about 1:20 to about 1:15, or about 1:17.5. In certain embodiments, the rapid expansion protocol (REP) utilizes a colloidal polymer nanomatrix covalently linked to humanized recombinant CD3 and CD28 agonists (e.g., antibodies). GMP T Cell TransAct TM In one embodiment, 1 mL of TransAct can be used to a final volume of 17.5 mL of REP cell culture medium. The REP TILs are then washed, formulated, and / or cryopreserved.

[0077] "Tumor infiltrating lymphocytes" or "TILs" may refer to a population of cells that were originally obtained as white blood cells that have left the bloodstream of a subject and migrated into a tumor. TILs include, but are not limited to, T cells (such as CD8 + Cytotoxic T cells, Th1 and Th17CD4 +TIL can include (or can be) tumor infiltrating T cells. TIL includes primary and secondary TIL. Primary TIL is obtained from patient tissue samples as described herein. Secondary TIL is any TIL cell population that has been amplified or propagated as discussed herein, including but not limited to bulk TIL and amplified TIL ("REP TIL" or "TIL after REp"). TIL cell populations may include genetically modified TIL. TIL can be typically determined biochemically when using cell surface markers or functionally determined according to its ability to infiltrate tumors and achieve treatment. TIL can be generally classified according to expression of one or more of the following biomarkers: CD3, CD4, CD8, TCRα / β, CD27, CD28, CCR7, CD62L, CD45RA, CD45RO, CD95, PD-1, TIM-3, LAG-3, 4-1BB and CD25. Additionally or alternatively, TILs can be functionally defined based on their ability to infiltrate solid tumors when reintroduced into a patient. Fisher et al., Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma, J. Clin. Oncol., 1989, 7(2): 250-61.

[0078] The term "IL-2" (or "IL2") refers to a T cell growth factor called interleukin-2, and includes all forms of IL-2, including human and mammalian forms, conservative amino acid substitutions, glycoforms, biosimilars, and variants thereof. IL-2 is described, for example, in Nelson, J. Immunol. 2004, 172, 3983-88 and Malek, Annu. Rev. Immunol. 2008, 26, 453-79, the disclosures of which are incorporated herein by reference. IL-2 may encompass human, recombinant forms of IL-2 such as aldesleukin And recombinant IL-2 forms. Aldesleukin (des-alanyl-1, serine-125 human IL-2) is a non-glycosylated human recombinant form of IL-2. IL-2 can also cover PEGylated forms of IL-2, including PEGylated IL2 prodrug NKTR-214. Alternative forms of conjugated IL-2 suitable for the present invention are described in the following documents: U.S. Patent Nos. 4,766,106, 5,206,344, 5,089,261 and 4,902,502, the disclosures of which are incorporated herein by reference. IL-2 preparations suitable for the present invention are described in U.S. Patent No. 6,706,289, the contents of which are incorporated herein by reference.

[0079] The first amplification (preparatory REP) can be performed in a closed container having a first gas permeable surface area. The second amplification (REP) can be performed in a closed container having a second gas permeable surface area. In some embodiments, the closed container comprises (or is) a single bioreactor. In some embodiments, the closed container comprises (or is) Container and / or Xuri TM In some embodiments, the sealed container is Device and / or Xuri TM W25 bioreactor. In some embodiments, the closed container comprises (or is) 10M and / or 100M. In some embodiments, the sealed container comprises (or is) 10M, 100M and / or Xuri TM W25 bioreactor. In certain embodiments, the methods of the invention (e.g., in the preparation of REP and / or REP TIL culture methods) include the use of a gas-permeable rapid expansion The device is used as a TIL culture container. In one embodiment, TILs are expanded in a gas permeable bag. In one embodiment, a gas permeable bag such as a Xuri TM In one embodiment, a cell expansion system for expanding TILs in a gas permeable bag, such as a shaking bag bioreactor system (also known as a Xuri Bioreactor system), is used to expand TILs. TM Cellbag expansion system (5) to expand TIL. In one embodiment, the cell expansion system includes a gas permeable cell bag. In one embodiment, TIL can be Bottle amplification.

[0080] In some embodiments, the closed system uses one container from the time the tumor fragments are obtained until the TILs are ready to be administered to the patient or cryopreserved. In some embodiments, when two containers are used, the first container is closed. container and without opening the first closed In the case of a single-cell container, the TIL population is centrifuged and transferred to an infusion bag.

[0081] The present disclosure also provides tumor infiltrating lymphocytes obtained by the method of the present invention.

[0082] The present disclosure also encompasses a cell population enriched for or expanded from tumor infiltrating lymphocytes, the cell population comprising one or more of the following:

[0083] (i) Percentage of CD3 + About 3% to about 88% of cells are CD3 + CD8 + T cells,

[0084] (ii) Percentage of CD3 + About 10% to about 96% of cells are CD3 + CD4 + T cells,

[0085] (iii) Percentage of CD4 + Cells from about 50% to about 88% CD4 + T CM T cells,

[0086] (iv) Percentage of CD8 + Cells from about 28% to about 82% CD8 + T CM T cells,

[0087] (v) Percentage of CD4 + Cells from about 11% to about 49% CD4 + T EM T cells, and

[0088] (vi) Percentage of CD8 + Cells from about 11% to about 61% CD8 + T EM T cells, wherein the cell population comprises no less than 70% viable cells, and wherein the cell population is generated from a tumor sample from a patient.

[0089] In certain embodiments, the cell population may contain no less than 80% CD3 + T cells.

[0090] In certain embodiments, a cell population may comprise a percentage of CD4 + Cells from about 10% to about 51% CD4 + CD27 + T cells.

[0091] In certain embodiments, a cell population may comprise a percentage of CD8 + Cells from about 12% to about 72% CD8 + CD27 + T cells.

[0092] In certain embodiments, a cell population may comprise a percentage of CD8 + Cells are approximately 34% to approximately 95% CD8 + CD28 + T cells.

[0093] In certain embodiments, a cell population may comprise a percentage of CD4 + Cells from about 82% to about 100% CD4 + CD28 + T cells.

[0094] In certain embodiments, a cell population may comprise a percentage of CD4 + About 0.2% to about 5.8% of cells are CD4 + 4-1BB + T cells.

[0095] In certain embodiments, a cell population may comprise a percentage of CD8 + About 0.2% to about 11.6% of cells are CD8 + 4-1BB + T cells.

[0096] In certain embodiments, a cell population may comprise a percentage of CD4 + Cells from about 0.2% to about 19.5% CD4 + LAG3 + T cells.

[0097] In certain embodiments, a cell population may comprise a percentage of CD8 + Cells from about 6% to about 51.2% CD8 + LAG3 + T cells.

[0098] In certain embodiments, a cell population may comprise a percentage of CD4 + Cells from about 0.9% to about 31% CD4 + PD1 + T cells.

[0099] In certain embodiments, a cell population may comprise a percentage of CD8 + About 1% to about 18% of cells are CD8 + PD1 + T cells.

[0100] In certain embodiments, the cell population may comprise no more than 10% CD56+ NK cells.

[0101] The present disclosure provides a cell population generated by a method of expanding tumor infiltrating lymphocytes (TILs). The method may include: (a) culturing a first cell population in a first cell culture medium to generate a second cell population, wherein the first cell population is obtained from a tumor sample of a patient; and (b) contacting the second cell population with a polymer matrix containing an anti-CD3 antibody and an anti-CD28 antibody or a fragment thereof in a second cell culture medium, wherein the second cell culture medium contains about 100 IU / mL to about 8000 IU / mL interleukin-2 (IL-2).

[0102] The present disclosure provides a method for expanding a cell population enriched for tumor-infiltrating lymphocytes. The method may include: (a) culturing cells obtained from a tumor sample of a patient; (b) treating the cultured cells to generate a cell population enriched for tumor-infiltrating lymphocytes, wherein the cell population comprises one or more of the following:

[0103] (i) Percentage of CD3 + About 3% to about 88% of cells are CD3 + CD8 + T cells,

[0104] (ii) Percentage of CD3 + About 10% to about 96% of cells are CD3 + CD4 + T cells,

[0105] (iii) Percentage of CD4 + Cells from about 50% to about 88% CD4 + CD45RA-CD62L+ central memory T cells,

[0106] (iv) Percentage of CD8 + Cells from about 28% to about 82% CD8 + CD45RA-CD62L+ central memory T cells,

[0107] (v) Percentage of CD4 + Cells from about 11% to about 49% CD4 + CD45RA-CD62L- effector memory T cells, and

[0108] (vi) Percentage of CD8 + Cells from about 11% to about 61% CD8 + T CD45RA-CD62L- effector memory T cells.

[0109] The present disclosure also provides a cell population enriched for tumor-infiltrating lymphocytes obtained by the method of the present invention.

[0110] The method of the present invention can use any suitable cell culture medium. In certain embodiments, the method of the present invention uses one or more types of cell culture medium. Available cell culture medium includes but is not limited to AIM-V culture medium (L-glutamine, 50 μ g / ml of streptomycin sulfate and 10 μ g / ml of gentamicin sulfate) (Thermo Fisher) and RPMI1640 culture medium.

[0111] The IL-2 concentration (in the first culture medium or the second culture medium) can be about 1000 IU / mL to about 10000 IU / mL, about 2000 IU / mL to about 10000 IU / mL, about 3000 IU / mL to about 10000 IU / mL, about 4000 IU / mL to about 10000 IU / mL, about 5000 IU / mL to about 10000 IU / mL, about 2000 IU / mL to about 8000 IU / mL, about 3000 IU / mL to about 7000 IU / mL or about 4000 IU / mL to about 6000 IU / mL. The IL-2 concentration (in the first culture medium or the second culture medium) can be about 6000 IU / mL. The IL-2 concentration (in the first medium or the second medium) can also be about 2000 IU / mL, 3000 IU / mL, 4000 IU / mL, 5000 IU / mL, 6000 IU / mL, 7000 IU / mL, 8000 IU / mL, 9000 IU / mL or up to about 10000 IU / mL.

[0112] Once TILs are expanded, they can be subjected to in vitro assays to determine their properties and / or functions such as tumor reactivity. For example, TILs can be evaluated by FACS for CD3, CD4, CD8, and CD58 expression. TILs can also be subjected to co-culture assays, cytotoxicity assays, ELISA assays, or ELISPOT assays.

[0113] Tumor samples can be obtained from any mammal. The cells or pharmaceutical compositions of the present invention can be used to treat any mammal. The mammal can be a human or a non-human primate. Mammals also include, but are not limited to, mammals of the following orders: Logomorpha, such as rabbits; Carnivora, including cats (cats) and dogs (dogs); Artiodactyla, including cattle (cows) and pigs (pigs); or Perssodactyla, including horses (horses). The mammal is preferably a non-human primate, for example, Primates, Ceboids or Simoids (monkeys) or Anthropoids (humans and apes). In some embodiments, the mammal can be a rodent mammal, such as mice and hamsters.

[0114] Obtaining tumor samples

[0115] Typically, TILs are initially obtained from a patient tumor sample (a first cell population) and subsequently expanded into a larger population for further manipulation as described herein, optionally cryopreserved.

[0116] TIL can be amplified from tumor samples or tissues or organs suffering from cancer. In some embodiments, TIL is obtained from tumor fragments. In some embodiments, tumor (sample) can be cut from non-cancerous tissue or necrotic area. Patient tumor samples can be obtained using methods known in the art, for example, by surgical resection, puncture biopsy or other means for obtaining a sample containing a mixture of tumor and TIL cells. Once obtained, the tumor sample can be fragmented (for example, using a sharp scalpel) into small pieces. The first cell colony can be one or more tumor fragments from a patient (or more than one patient). The first cell colony can be obtained from one or more tumor fragments, and the tumor fragments are from the tumor removed from the patient. The method for destroying a tumor can include mechanical fragmentation such as tumor tissue fragmentation, slicing, segmentation and shredding and any other method for destroying the physical structure of tumor tissue.

[0117] In some embodiments, tumor fragments are between about 1 mm 3 With 50mm 3 Between, about 1mm 3 With 45mm 3 Between, about 1mm 3 With 40mm 3 Between, about 1mm 3 With 35mm 3 Between, about 1mm 3 With 30mm 3 Between, about 1mm 3 With 25mm 3Between, about 1mm 3 With 20mm 3 Between, about 1mm 3 With 1 5mm 3 Between, about 1mm 3 With 10mm 3 Between, about 1mm 3 With 8mm 3 Between, about 2mm 3 With 3mm 3 Between, about 1mm 3 , about 2mm 3 , about 3mm 3 , about 4mm 3 , about 5mm 3 , about 6mm 3 、About 7mm 3 , about 8mm 3 、About 9mm 3 , about 10mm 3 , about 12mm 3 , about 15mm 3 , about 18mm 3 , about 20mm 3 , about 25mm 3 or about 30mm 3 In some embodiments, the plurality of fragments comprises about 4 to about 50 fragments, wherein each fragment has a diameter of about 8 mm. 3 To about 27mm 3 In some embodiments, the plurality of fragments comprises a total volume of about 1300 mm 3 To about 1500mm 3 In some embodiments, the plurality of fragments comprises a total volume of about 1350 mm 3 In some embodiments, the plurality of fragments comprises about 50 fragments having a total mass of about 1 gram to about 1.5 grams.

[0118] In some embodiments, the tumor can be fragmented to about 2-3 mm in each dimension. In some cases, the tumor can be fragmented to about 0.5 mm to about 5 mm, about 1 mm to about 2 mm, about 2 mm to about 3 mm, about 3 mm to about 4 mm, or about 4 mm to about 5 mm in each dimension.

[0119] TILs can be cultured from these tumor fragments using enzymatic tumor digestion. Such tumor digests can be produced by incubation in an enzymatic medium (e.g., DNA enzyme and collagenase) followed by mechanical dissociation (e.g., using a tissue dissociator). In some embodiments, fragmentation includes physical fragmentation (e.g., dissection) and / or digestion.

[0120] The method may include obtaining a bulk T cell population from a tumor sample by any suitable method known in the art. For example, a bulk T cell population may be obtained from a tumor sample by dissociating the tumor sample into a cell suspension from which a specific cell population may be selected. Suitable methods for obtaining a bulk T cell population may include, but are not limited to, any one or more of the following: mechanical dissociation (e.g., mincing) of a tumor, enzymatic dissociation (e.g., digestion) of a tumor, and aspiration (e.g., such as with the aid of a needle).

[0121] In certain embodiments, tumor sample is from solid tumor, comprises primary tumor, invasive tumor or metastatic tumor.Solid tumor can be benign or malignant.Term " solid tumor cancer " refers to malignant, neoplastic or cancerous solid tumor.Solid tumor can include sarcoma, hepatocellular carcinoma, glioma, head and neck cancer, bone cancer, brain cancer, breast cancer, anal cancer, anal canal cancer, anorectal cancer, eye cancer, intrahepatic bile duct cancer, joint cancer, cervical cancer, gallbladder cancer, pleural cancer, nasal cancer, nasal cavity cancer, middle ear cancer, oral cancer, vulvar cancer, colon cancer, esophageal cancer, cervical cancer, gastrointestinal cancer, hypopharyngeal cancer, laryngeal cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, peritoneal cancer, omental cancer, mesenteric cancer, pharyngeal cancer, prostate cancer, rectal cancer, kidney cancer, small intestine cancer, soft tissue cancer, gastric cancer, testicular cancer, thyroid cancer, ureteral cancer, bladder cancer or its combination. In some embodiments, the cancer is selected from cervical cancer, head and neck cancer (including, for example, head and neck squamous cell carcinoma (HNSCC)), glioblastoma, ovarian cancer, sarcoma, pancreatic cancer, bladder cancer, breast cancer, and non-small cell lung cancer.

[0122] Tumor samples can also be obtained from liquid tumors, such as tumors obtained from hematological malignancies.

[0123] TILs can be expanded from tumor samples derived from donors of any developmental stage, including but not limited to fetuses, neonates, infants, and adults.

[0124] The tumor fragments can then be cultured in vitro using culture medium and cell stimulators such as cytokines. In some cases, IL-2 can be used to expand TILs from tumor fragments.

[0125] Second amplification preparation REP)

[0126] The prepared REP TIL expanded by the method of the present invention can generate REPTIL whose CD8 / CD4 ratio is not significantly reduced. The prepared REP TIL of the present invention can be expanded while maintaining a low expression level of the exhaustion marker PD-1 in the REP TIL.

[0127] In the first expansion (preparatory REP, step (a) of the method), the first cell culture medium may contain about 1000 IU / mL to about 10000 IU / mL IL-2, about 1000 IU / mL to about 9000 IU / mL IL-2, about 1000 IU / mL to about 8000 IU / mL IL-2, about 2000 IU / mL to about 8000 IU / mL IL-2, about 2000 IU / mL to about 7000 IU / mL IL-2, about 2000 IU / mL to about 6000 IU / mL IL-2, about 2000 IU / mL to about 5000 IU / mL IL-2, about 2000 IU / mL to about 4000 IU / mL IL-2, about 2000 IU / mL to about 3000 IU / mL IL-2. IL-2, about 3000 IU / mL to about 8000 IU / mL IL-2, about 3000 IU / mL to about 7000 IU / mL IL-2, about 3000 IU / mL to about 6000 IU / mL IL-2, about 3000 IU / mL to about 5000 IU / mL IL-2, about 4000 IU / mL to about 8000 IU / mL IL-2, about 2000 IU / mL IL-2, about 3000 IU / mL IL-2, about 4000 IU / mL IL-2, about 5000 IU / mL IL-2, about 6000 IU / mL IL-2, about 7000 IU / mL IL-2, about 8000 IU / mL IL-2, about 9000 IU / mL IL-2, or about 10000 IU / mL In some embodiments, the first cell culture medium may comprise about 3000 IU / mL IL-2. In some embodiments, the first cell culture medium may comprise about 5000 IU / mL IL-2. In some embodiments, the first cell culture medium may comprise about 6000 IU / mL IL-2. In some embodiments, the first cell culture medium may comprise about 7000 IU / mL IL-2. In some embodiments, the first cell culture medium may comprise about 8000 IU / mL IL-2.

[0128] In the first expansion (preparatory REP, step (a) of the method), the first cell population can be cultured (the first expansion can last) for about 3 days to about 60 days, about 5 days to about 50 days, about 7 days to about 40 days, about 10 days to about 40 days, about 10 days to about 30 days, about 10 days to about 20 days, about 10 days to about 18 days, about 10 days to about 17 days, about 10 days to about 16 days, about 12 days to about 15 days, about 12 days to about 14 days, about 13 days to about 14 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days or about 20 days. In some embodiments, the first cell population is cultured for about 14 days. In some embodiments, the first expansion lasts for about 14 days.

[0129] In the first expansion (preparatory REP, step (a) of the method), the cell culture medium can be added (or replaced) once, twice, three times or four times, at which time the first cell population has been cultured for about 2 or 3 days (when day 0 is the start day of culturing the first cell population, on or about day 3), about 3 or 4 days (on or about day 4), about 4 or 5 days (on or about day 5), about 5 or 6 days (on or about day 6), about 6 or 7 days (on or about day 7), about 7 or 8 days (on or about day 8), about 8 or 9 days (on or about day 9), about 9 or 10 days (on or about day 10), about 10 or 11 days (on or about day 11), about 11 or 12 days (on or about day 12), about 12 or 13 days (on or about day 13) or about 13 or 14 days (on or about day 14). In certain embodiments, in the first expansion (preparatory REP, step (a) of the method), the cell culture medium is added once on or around day 9 (at which point the first cell population has been cultured for about 8 or 9 days). In certain embodiments, in the first expansion (preparatory REP, step (a) of the method), the cell culture medium is added once on or around day 10 (at which point the first cell population has been cultured for about 9 or 10 days). In certain embodiments, in the first expansion (preparatory REP, step (a) of the method), the cell culture medium is added once on or around day 11 (at which point the first cell population has been cultured for about 10 or 11 days).

[0130] In certain embodiments, in the first expansion (preparatory REP, step (a) of the method), the volume of the cell culture medium added is about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 1.1 times, about 1.2 times, about 1.3 times, about 1.4 times, about 1.5 times, about 1.6 times, about 1.7 times, about 1.8 times, about 1.9 times, about 2 times, about 2.2 times, about 2.5 times, about 2.7 times or about 3 times the volume of the cell culture medium in the cell culture container.

[0131] The initial culture volume for the first expansion (preparatory REP, step (a) of the method) can be about 5% to about 100%, about 10% to about 80%, about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, about 20% to about 80%, about 20% to about 60%, about 20% to about 50%, about 20% to about 40%, about 20% to about 30%, about 25% to about 80%, about 25% to about 60%, about 25% to about 50%, about 25% to about 40%, about 25% to about 30%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55% or about 60% of the capacity of the cell culture vessel / system. In certain embodiments, the initial culture volume used for the first expansion (preparatory REP, step (a) of the method) is about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, or about 40% of the capacity of the cell culture vessel / system. In certain embodiments, 10 mL, 15 mL, 20 mL, 25 mL, 30 mL, 35 mL, or 40 mL initial culture volume is used. 10M device (bottom area 10cm 2 , 100 mL capacity). In certain embodiments, 100 mL, 150 mL, 200 mL, 250 mL, 300 mL, 350 mL, or 400 mL initial culture volume is used. 100M device (bottom area 100cm 2 , 1000mL capacity).

[0132] The first amplification (preparatory REP) can produce a range of about 1×10 7 to about 1×10 9 TIL or cells, about 2×10 7 About 9×10 8 TIL or cells, about 3×10 7 About 8×10 8 TILs or cells, about 4×10 7 About 6×10 8 TILs or cells, about 5×10 7 About 5×10 8 TILs or cells, about 6×10 7 About 4×10 8 TILs or cells, about 8×10 7 About 3×10 8 TIL or cells, about 9×10 7 about 2×10 8TIL or cells, about 9×10 7 to about 1×10 8 TILs or cells, or about 1×10 8 A cell population or TIL of a TIL or cell.

[0133] Second expansion (REP)

[0134] The second amplification is generally referred to as a rapid amplification process (REP). The second amplification of the method of the present invention may or may not use feeder cells. In one embodiment, the method of the present invention or the second amplification of the method of the present invention is a feeder-free process.

[0135] In the second expansion (REP, step (b) of the method), the second cell culture medium can contain about 50 IU / mL to about 10000 IU / mL IL-2, about 100 IU / mL to about 8000 IU / mL IL-2, about 200 IU / mL to about 6000 IU / mL IL-2, about 500 IU / mL to about 6000 IU / mL IL-2, about 500 IU / mL to about 4000 IU / mL IL-2, about 500 IU / mL to about 3000 IU / mL IL-2, about 800 IU / mL to about 5000 IU / mL IL-2, about 800 IU / mL to about 4000 IU / mL IL-2, about 1000 IU / mL to about 6000 IU / mL IL-2, or about 1000 IU / mL to about 4000 IU / mL IL-2. In one embodiment, the second cell culture medium comprises about 3000 IU / mL IL-2.

[0136] In the second expansion (REP, step (b) of the method), the contacting can be about 3 days to about 17 days, about 3 days to about 60 days, about 5 days to about 50 days, about 7 days to about 40 days, about 10 days to about 40 days, about 10 days to about 30 days, about 10 days to about 20 days, about 10 days to about 14 days.

[0137] In some embodiments, the second expansion (REP, step (b) of the method) can be advanced by 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days. In some embodiments, the second TIL expansion can be advanced by about 7 days to about 14 days. In some embodiments, the second TIL expansion can be advanced by about 8 days to about 14 days. In some embodiments, the second TIL expansion can be advanced by about 9 days to about 14 days. In some embodiments, the second TIL expansion can be advanced by about 10 days to about 14 days. In some embodiments, the second TIL expansion can be advanced by about 11 days to about 14 days. In some embodiments, the second TIL expansion can be advanced by about 12 days to about 14 days. In some embodiments, the second TIL expansion can be advanced by about 13 days to about 14 days. In some embodiments, the second TIL expansion can be advanced by about 14 days.

[0138] In the second expansion (REP, step (b) of the method), the contacting can occur, for example, in vitro in any container capable of containing the cells, preferably under a sterile environment. Such containers can be, for example, culture bottles, culture bags, bioreactors, or any device that can be used to culture, including culturing cells in a closed cell culture system or a closed container. The closed system or container can provide a gas permeable surface area. In one embodiment, the second expansion (REP, step (b) of the method) can use T-175 bottles, gas permeable bags and / or gas permeable culture systems (e.g., ). In some embodiments, the second amplification (REP, step (b) of the method) is performed in a closed system or a closed system bioreactor. In some embodiments, the closed system bioreactor is a single bioreactor. In one embodiment, the second amplification can be performed in a closed system or a closed system bioreactor. 10M and / or It is carried out in 100M.

[0139] In some embodiments, the third cell population is at least 100 times greater in number than the second cell population, e.g., about 100 times to about 2000 times greater in number, about 100 times to about 1800 times greater in number, about 100 times to about 1500 times greater in number, about 100 times to about 1200 times greater in number, about 100 times to about 1000 times greater in number, about 100 times to about 800 times greater in number, about 100 times to about 600 times greater in number, or about 100 times to about 500 times greater in number than the second cell population.

[0140] The third cell population can be a therapeutic TIL population. In some embodiments, the therapeutic TIL population comprises enough TIL for a therapeutically effective dose of TIL.

[0141] In some embodiments, the third cell population comprises effector T cells and / or central memory T cell subsets increased relative to the second TIL population.In some embodiments, the third population TIL retains the TCR library of the second TIL population to a greater extent.

[0142] Polymer matrix comprising anti-CD3 antibody and anti-CD28 antibody or fragments thereof

[0143] In certain embodiments, the methods of the invention generate, expand, activate and / or enrich TILs using a polymer matrix comprising an anti-CD3 antibody and an anti-CD28 antibody or fragments thereof.

[0144] Flexible matrix can comprise collagen, protein, peptide, polysaccharide, glycosaminoglycan and / or extracellular matrix composition (or be basically composed of or be composed of).Polysaccharide can comprise for example cellulose, agarose, dextran, chitosan, hyaluronic acid or alginate.Other polymers can comprise polyester, polyether, polyanhydride, polyalkyl cyanoacrylate, polyacrylamide, polyorthoester, polyphosphazene, polyvinyl acetate, block copolymer, polypropylene, polytetrafluoroethylene (PTFE) or polyurethane.Polymer can be lactic acid or copolymer.Copolymer can comprise lactic acid and / or glycolic acid (PLGA).Polymer matrix can comprise polymeric dextran material (or dextran polymer) (or be basically composed of or be composed of).

[0145] The polymer matrix may have an average molecular weight of 40,000 Daltons.

[0146] The polymer matrix may or may not contain magnetic, paramagnetic, superparamagnetic nanocrystals or fluorescent dyes (eg, embedded in the polymer matrix).

[0147] The polymer matrix may have a size of less than 1 μm, less than 500 nm, or less than 200 nm. The polymer matrix may have a size ranging from about 1 nm to about 500 nm, or from about 10 nm to about 200 nm.

[0148] Anti-CD3 antibodies or fragments thereof and anti-CD28 antibodies or fragments thereof can be attached to the same polymer matrix, or attached to a discrete polymer matrix. Anti-CD3 antibodies or fragments thereof and anti-CD28 antibodies or fragments thereof can be attached to or coupled to a polymer matrix by various methods known in the art. The attachment can be covalent or non-covalent, electrostatic or hydrophobic. The attachment can be achieved by a variety of attachment means, for example, including chemical, mechanical, enzymatic means or other suitable means. The antibody or fragment thereof can first be attached to the matrix directly or indirectly. For example, the antibody or fragment thereof can first be attached to the matrix by avidin (or streptavidin) and biotin system. The antibody or fragment thereof can be indirectly attached to the matrix, for example, indirectly attached by anti-isotype antibodies. Another example includes the use of protein A or protein G or other non-specific antibody binding molecules that are attached to the matrix to bind to the antibody or fragment thereof. Alternatively, the antibody or fragment thereof can be attached to the matrix by chemical means, such as cross-linking to the matrix.

[0149] Anti-CD3 and / or anti-CD28 antibodies can be polyclonal antibodies and monoclonal antibodies, chimeric antibodies, haptens and antibody fragments and molecules that are antibody equivalents because they specifically bind to epitopes on antigens. The term "antibody" includes any isotype (IgA, IgG, IgE, IgD, IgM) of polyclonal and monoclonal antibodies or antigen-binding portions thereof, including but not limited to F (ab) and Fv fragments such as scFv, single-chain antibodies, chimeric antibodies, humanized antibodies and Fab expression libraries. In certain embodiments, anti-CD3 and / or anti-CD28 antibodies can be monoclonal antibodies. Anti-CD3 antibodies include OKT-3, also known as muromonab. Anti-CD3 antibodies also include UHCT1 clones, also known as T3 and CD3e. Other anti-CD3 antibodies include, for example, otelixizumab, teplizumab and visilizumab.

[0150] The ratio of anti-CD3 antibody or fragment thereof to anti-CD28 antibody or fragment thereof (bound to the same polymer matrix, or bound to a separate polymer matrix) can range from about 100: 1 to about 1: 100, from about 10: 1 and about 1: 10, or from about 2: 1 and about 1: 2. The anti-CD3 antibody or fragment thereof and / or the anti-CD28 antibody or fragment thereof can be bound to the same or separate matrix at a high density of more than 25 μg / mg matrix or more than 50 μg / mg matrix.

[0151] In one embodiment, the polymer matrix is ​​TransAct TM . U.S. Patent No. 10,513,687.

[0152] In certain embodiments, the ratio of polymer matrix to cells may be greater than 100:1, greater than 500:1, or greater than 1000:1.

[0153] Pharmaceutical composition

[0154] The present disclosure provides a pharmaceutical composition comprising cells / TIL or cell colonies of the present invention. The pharmaceutical composition of the present invention may comprise cells or cell colonies of the present invention and pharmaceutically acceptable carriers or excipients. Pharmaceutically acceptable carriers or pharmaceutically acceptable excipients may include suitable solvents, dispersion media, coating agents, antibacterial and antifungal agents, isotonic and absorption delaying agents and inert ingredients. Additional active pharmaceutical ingredients, such as other drugs, may also be incorporated into the described compositions and methods. Suitable pharmaceutically acceptable carriers for cell injection may include any isotonic carriers such as, for example, saline (NaCl of about 0.9% w / v in water, about 300mOsm / L NaCl in water, or about 9.0g NaCl / liter of water) or about 5% dextrose in water. In one embodiment, the pharmaceutically acceptable carrier is supplemented with human serum albumin. The composition of the present disclosure may be prepared for intravenous administration. In one embodiment, the pharmaceutical composition is a TIL or cell suspension in a sterile buffer.

[0155] The cells or pharmaceutical compositions of the invention can be used in methods of treating diseases such as hyperproliferative diseases. They can also be used to treat other conditions. In some embodiments, the hyperproliferative disease is cancer.

[0156] The cells or cell colonies of the present invention can be used in methods for treating or preventing cancer. In this regard, the present disclosure provides a method for treating or preventing cancer in a mammal, the method comprising administering the pharmaceutical composition, cell or cell colony of the present invention to the mammal in an amount effective to treat or prevent cancer in the mammal. Another embodiment of the present invention provides a method for treating or preventing cancer in a mammal, the method comprising administering the cells or cell colonies of the present invention to the mammal in an amount effective to treat or prevent cancer in the mammal.

[0157] The present disclosure also encompasses a method for treating a subject (e.g., a mammal) or patient with cancer. The method may include administering the TIL of the present invention and / or the cell colony of the present invention to the subject or patient. The cells / TIL can be administered to the patient as a pharmaceutical composition.

[0158] Cells or pharmaceutical compositions of the present invention may be administered by any suitable route, including intranasal and transdermal routes, intraarterial routes, intravenous, intraperitoneal, parenteral, intramuscular, subcutaneous, topical, by transplantation or by inhalation. Cells or pharmaceutical compositions of the present invention may be administered by injection or infusion. In some embodiments, cells or pharmaceutical compositions of the present invention are administered by intraarterial or intravenous administration (e.g., infusion) methods. Other suitable routes of administration include intraperitoneal, intrathecal, and intralymphatic.

[0159] Any suitable dose of TIL may be administered. In some embodiments, about 2×10 10 About 15×10 10 TIL or cells, about 1×10 10 About 5×10 10 TIL or cells, about 3×10 10 About 12×10 10 TILs or cells, about 4×10 10 About 10×10 10 TILs or cells, about 5×10 10 About 8×10 10 TILs or cells, about 6×10 10 About 8×10 10 TILs or cells, about 7×10 10 About 8×10 10 TILs or cells, about 8×10 10 TILs or cells or about 7 × 10 10 In some embodiments, the therapeutically effective dose is about 2×10 10 About 15×10 10 In some embodiments, the therapeutically effective dose is about 1×10 10 About 5×10 10 In some embodiments, the therapeutically effective dose is about 3×10 10 About 12×10 10 In some embodiments, the therapeutically effective dose is about 4×10 10 to about 10×10 10 In some embodiments, the therapeutically effective dose is about 5×10 10 About 8×10 10 In some embodiments, the therapeutically effective dose is about 6×10 10 About 8×10 10 In some embodiments, the therapeutically effective dose is about 7×10 10About 8×10 10 In some embodiments, the effective dose of TIL is about 1×10 6 , 2×10 6 , 3×10 6 , 4×10 6 , 5×10 6 , 6×10 6 ,7×10 6 , 8×10 6 ,9×10 6 , 1×10 7 , 2×10 7 , 3×10 7 , 4×10 7 , 5×10 7 , 6×10 7 ,7×10 7 , 8×10 7 ,9×10 7 , 1×10 8 , 2×10 8 , 3×10 8 , 4×10 8 , 5×10 8 , 6×10 8 ,7×10 8 , 8×10 8 ,9×10 8 , 1×10 9 , 2×10 9 , 3×10 9 , 4×10 9 , 5×10 9 , 6×10 9 ,7×10 9 , 8×10 9 ,9×10 9 , 1×10 10 , 2×10 10 , 3×10 10 , 4×10 10 , 5×10 10 , 6×10 10 ,7×10 10 , 8×10 10 ,9×10 10 , 1×10 11 , 2×10 11 , 3×10 11 , 4×10 11 , 5×10 11 , 6×10 11 ,7×10 11 , 8×10 11,9×10 11 , 1×10 12 , 2×10 12 , 3×10 12 , 4×10 12 , 5×10 12 , 6×10 12 ,7×10 12 , 8×10 12 ,9×10 12 , 1×10 13 , 2×10 13 , 3×10 13 , 4×10 13 , 5×10 13 , 6×10 13 ,7×10 13 , 8×10 13 and 9×10 13 In some embodiments, the effective dose of TIL is 1×10 6 Up to 5×10 6 , 5×10 6 Up to 1×10 7 , 1×10 7 Up to 5×10 7 , 5×10 7 Up to 1×10 8 , 1×10 8 Up to 5×10 8 , to 1×10 9 Up to 5×10 9 , 5×10 9 Up to 1×10 10 , 1×10 10 Up to 5×10 10 , 5×10 10 Up to 1×10 11 , 5×10 11 Up to 1×10 12 , 1×10 12 Up to 5×10 12 and 5×10 12 Up to 1×10 13 In some embodiments, about 1×10 9 to about 1×10 11 cells or about 5×10 9 About 9×10 10 The number of cells / TIL can be about 10×10 6 to about 10×10 11 cells, approximately 10×109 About 10×10 cells 11 cells or 10×10 per administration (e.g., infusion) 7 to about 10×10 9 The pharmaceutical composition comprising TIL can be administered at 10 4 Up to 10 11 cells / kg body weight (e.g., 10 5 Up to 10 6 , 10 5 Up to 10 10 , 10 5 Up to 10 11 , 10 6 Up to 10 10 , 10 6 Up to 10 11 , 10 7 Up to 10 11 , 10 7 Up to 10 10 , 10 8 Up to 10 11 , 10 8 Up to 10 10 , 10 9 Up to 10 10 or 10 9 Up to 10 10 The dosage range is 100 cells / kg body weight (including all integer values ​​within these ranges).

[0160] The TIL provided in the pharmaceutical composition of the present invention can be effective in a wide range of dosages. The exact dosage may depend on the route of administration, the rate of administration, the severity of the disease or condition, the sex and age of the subject to be treated, and the weight of the subject to be treated. As needed, clinical existing TIL dosages may also be used.

[0161] The cells or pharmaceutical compositions of the present invention can be administered in a single dose or in multiple doses. Such administration can be performed by injection (e.g., intravenous injection). In some embodiments, the cells or pharmaceutical compositions of the present invention are administered as a single intra-arterial or intravenous infusion. Administration can be once, twice, three times, four times, five times, six times or more per year. Administration can be once a month, once every two weeks, once a week, or once every two days. As long as necessary, TIL administration can continue.

[0162] For the purposes of the methods of the invention, where a cell population is administered, the cells may be allogeneic or autologous to the mammal. In one embodiment, the cells are autologous to the mammal.

[0163] The cancer treated by the cell or pharmaceutical composition of the present invention can be melanoma, ovarian cancer, cervical cancer, non-small cell lung cancer (NSCLC), lung cancer, bladder cancer, breast cancer, cancer caused by human papillomavirus, head and neck cancer (including head and neck squamous cell carcinoma (HNSCC)), kidney cancer, renal cell carcinoma, colorectal cancer or other types of cancer. The cell or pharmaceutical composition of the present invention can be used to treat relapsed or refractory non-small cell lung cancer (NSCLC). The cancer can be any cancer, including any of the following: sarcoma (e.g., synovial sarcoma, osteogenic sarcoma, cervical leiomyosarcoma and alveolar rhabdomyosarcoma), lymphoma (e.g., Hodgkin's lymphoma and non-Hodgkin's lymphoma), hepatocellular carcinoma, glioma, head-neck cancer, acute lymphocytic cancer, acute myeloid leukemia, bone cancer, brain cancer, breast cancer, anal cancer, anal canal cancer or anorectal cancer, eye cancer, intrahepatic bile duct cancer, joint cancer, cervical cancer, gallbladder cancer or pleural cancer: nasal cancer, nasal cancer or middle ear cancer cancer, oral cancer, vulvar cancer, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer (e.g., colon cancer), esophageal cancer, cervical cancer, gastrointestinal cancer (e.g., gastrointestinal carcinoid tumors), hypopharyngeal cancer, laryngeal cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, cancer of the peritoneum, omentum and mesentery, pharyngeal cancer, prostate cancer, rectal cancer, kidney cancer, small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, ureter cancer, and bladder cancer.

[0164] In some embodiments, the hyperproliferative disease is a solid tumor cancer. In some embodiments, the solid tumor cancer is selected from melanoma, ovarian cancer, cervical cancer, non-small cell lung cancer (NSCLC), lung cancer, bladder cancer, breast cancer, cancer caused by human papillomavirus, head and neck cancer (including head and neck squamous cell carcinoma (HNSCC)), kidney cancer and renal cell carcinoma. In some embodiments, the hyperproliferative disease is a hematological malignancy. In some embodiments, the solid tumor cancer is chronic lymphocytic leukemia, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, follicular lymphoma and mantle cell lymphoma.

[0165] In one embodiment, the method of treating cancer in a patient further comprises pre-treating the patient with non-bone marrow eradication chemotherapy prior to administering the cells or pharmaceutical compositions of the invention. In one embodiment, the non-bone marrow eradication chemotherapy comprises administering cyclophosphamide and / or fludarabine prior to TIL infusion. In one embodiment, after the non-bone marrow eradication chemotherapy and TIL infusion, the patient receives an intravenous infusion of IL-2.

[0166] The term "about" when referring to a reference numerical value means ±10% of the numerical value. That is, the numerical value may be within the range of 90% to 110% of the numerical value.

[0167] Without further elaboration, it is believed that based on the above description, those skilled in the art can utilize the present disclosure to its fullest extent. Therefore, the following specific embodiments should be interpreted as merely illustrative and not limiting the remainder of the present disclosure in any way. All publications cited herein are incorporated by reference for the purposes or themes mentioned herein.

[0168] Example 1: TIL preparation REP process development and preparation REP TIL characterization

[0169] In the pre-rapid expansion protocol (preparatory REP), autologous tumor infiltrating lymphocytes (TIL) are harvested from the patient's NSCLC tumor sample. The tumor is first fragmented and cultured under high doses of IL-2 to promote TIL departure and expansion. After this initial ex vivo culture, TIL can be further expanded with a rapid expansion protocol (REP) to achieve a therapeutic dose. We have optimized the REP TIL culture method that can be transferred to GMP production.

[0170] The initial T cell material (preparatory REP TIL) can be cryopreserved until the patient's condition progresses after standard of care therapy. After the patient progresses, the preparatory REP TIL can be thawed and expanded according to the rapid expansion protocol (REP).

[0171] Our optimized REP-prepared TIL culture method involves rapid expansion using a gas-permeable The device serves as a TIL culture vessel and is implemented with a short culture time and medium exchange frequency to support a robust GMP production process that produces ready-REP TILs with high cell yields and favorable T cell phenotypes suitable for further manufacturing. Culture medium can be added on or around day 8, day 9, day 10 and / or day 11 (day 0 is the day when cell culture (first expansion or ready-REP) begins) and ready-REP TILs can be harvested on or around day 12, day 13, day 14, day 15, day 16 or day 17. Using the optimized protocol, IL-2 levels and glucose levels remain sufficiently high, while the growth inhibitory metabolite lactate is at a low level that does not impair TIL expansion. We demonstrated after optimization that the average number of TILs produced per tumor fragment was more than 4 times higher than the number of TILs produced by optimization (16.29×10 6 ±10.58×10 6 Compare 3.10×10 6 ±3.52×10 6 ), which represents an overall superior yield of primed REP TILs. Primed REP TILs display an early differentiation state, with predominantly T central memory cells - CD27 + A higher percentage of cells (CD4+ Among the compartments, 66.28% ± 12.87% and CD8 + compartment; 59.04% ± 13.47%; n = 8) and the proportion of effector cells was very low (CD4 + Neutralize CD8 + In addition, T N / T SCM The percentage of subpopulations was also high in the harvested products, suggesting a more favorable TIL characterization 1 .

[0172] In one embodiment, the rapid expansion protocol (REP) utilizes a colloidal polymer nanomatrix covalently linked to humanized recombinant CD3 and CD28 agonists (e.g., antibodies) GMP T Cell TransAct TM The REPTIL is then washed, formulated and / or stored frozen.

[0173] During the preparatory REP period, previously shown The fragmented melanoma tumors cultured in the device produced an average of 7.51×10 6 TIL / tumor fragment 2 Based on an estimated 400 REP amplifications and a minimum of 1 × 10 9 The target TIL dose for our REP preparation was 6 × 10 7 CD3 + T cells 3 Appropriate conditions that favor the growth of primed REP TILs and the preservation of their early differentiated phenotype will generate high-quality intermediates, which are expected to facilitate the manufacture of finished REP TILs with high therapeutic potential. 4,5 This study sought to optimize key culture conditions to generate a high-yield REP-ready TIL product with an early differentiation phenotype and shortened culture time.

[0174] method

[0175] Tumor collection

[0176] Non-small cell lung cancer tumor specimens were collected. NSCLC specimens were de-identified and an identification number was assigned to each donor. Briefly, the resected tumor samples were submerged in tissue protection solution at 4°C and shipped within 24 hours of surgery. Tumor samples were transferred immediately upon receipt for the preparation of TILs.

[0177] Tumor fragmentation and seeding

[0178] Only one tumor was processed at a time and a new set of materials and equipment was used for each tumor.

[0179] Tumor wash medium was added to each well of a 6-well plate for washing. Tumor wash medium was added to a culture dish for tumor fragmentation. Using tweezers, the tumor was transferred to the culture dish. The tumor was dissected into fragments of approximately 2-3 mm in each dimension. Necrotic areas, hemorrhagic areas, and adipose tissue areas were removed during fragmentation. Each tumor fragment was washed to remove red blood cells. This process was repeated until the entire tumor section was dissected. The number of tumor fragments was recorded and fragments from the same donor were combined for culture in the same culture device.

[0180] To use 10M device, 1, 2, 3, 4, 5, 6, 7 or 8 tumor fragments from the same donor were inoculated in one 10M device. In order to use The 100M device seeded up to 100 tumor fragments from the same donor in one 100M device.

[0181] Cultivation of REP TIL

[0182] Preparatory REP TILs were cultured in preparatory REP basal medium supplemented with 300 IU / mL, 1000 IU / mL, 3000 IU / mL or 6000 IU / mL IL-2. The basal medium contained RPMI-1640, human AB serum, HEPES, (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), β-ME (2-mercaptoethanol), GlutaMax and gentamicin.

[0183] On day 0 after tumor fragmentation, tumor fragments were inoculated in For small-scale preparatory REP, add 1-8 fragments to a 10 mL, 20 mL, 25 mL, 30 mL, 50 mL, or 100 mL initial culture volume. 10M device.

[0184] Cell counting

[0185] use NC-200 TM The system measures cell concentration, viability and size.

[0186] Collect TIL culture medium samples

[0187] If the spent medium is removed before cell counting, save 500 μL of the spent medium in a -20°C freezer for later analysis. Alternatively, if cell counting is not performed, collect a small volume (about 500 μL at a time) of the pre-REP medium from near the surface of the medium. Remove the medium from the pre-REP medium at the indicated time points during the pre-REP phase (e.g., days 0, 3, 6, 7, 10, and 14). 10M device or 100M device sampling.

[0188] Quantification of glucose and lactate concentrations in culture

[0189] Glucose and lactate concentrations in the culture supernatants were measured by the Glucose-Glo assay and the Lactate-Glo assay.

[0190] Quantification of IL-2 concentration by ELISA

[0191] The IL-2 ELISA kit from Thermo Fisher Scientific, Inc. was used to quantify IL-2 protein concentration. Samples were measured in duplicate or triplicate wells, and data were presented as mean ± standard deviation (SD). Protein concentration (pg / mL) was converted to IU / mL (for IL-2, 1 ng / mL = 16.36 IU / mL).

[0192] Flow cytometry

[0193] The cells were first treated with LIVE / DEAD TM Fixable Aqua (Thermo Fisher Scientific, Inc.) staining was followed by staining with antibodies against various surface markers. Samples were then acquired by CytoFLEX LX flow cytometer. All data were analyzed using FlowJo V10 software.

[0194] Results and Analysis

[0195] As an alternative to bottles and bags for young TIL methods, (Galvanic Rapid Expansion) is a production platform created specifically for the production of immune cells that is easy to scale up, expand, and is compatible with the cGMP conditions required for clinical trials. 10 devices were used to compare initial TIL growth (prepared REP)2. The device serves as a preparatory REP TIL culture vessel.

[0196] We first used four matched tumor sample groups (T5101001, T5101002, T5101004, and T5101005) to The final yield of prepared REP cells from 4 donors was (15.60±25.09)×10 6 cells to (27.54±22.60)×10 6 cells.

[0197] Phenotyping of REP TILs showed that a large proportion of TILs were CD4 + Cells and CD8 + T cells have a central memory phenotype CM (central memory T cells), rather than effector phenotypes, i.e., T EM (Effector memory T cells).

[0198] Glucose and lactate levels as well as IL-2 consumption in preparatory REP cultures were measured to optimize feeding. We next scaled up the process to use 100M device (bottom area 100cm 2 , 1000mL capacity). Tumor fragments were used to start the preparatory REP culture of 3 donors (T5101009, T5101010 and T5101013). The preparatory REP runs of T5101009 and T5101010 were performed before the culture time was determined and stopped at the 17th or 20th day, respectively, without any culture medium addition or exchange. For T5101013, cell counting was performed and fresh culture medium was added at or around the 8th, 9th, 10th or 1st day. The glucose levels of T5101010 and T5101013 began to decline after the 6th day, while there was greater cell expansion compared to T5101009. As of the 3rd day, T5101010 was detected to produce more lactate and this production continued to increase throughout the culture period. For T5101013, the addition of fresh culture medium did seem to prevent the lactate level from increasing further. This addition to the medium will be particularly important for donors with rapidly growing TILs in order to keep lactate at low levels that are tolerable to T cells.

[0199] We further evaluated IL-2 consumption in pre-REP cultures. IL-2 protein concentration was measured with an ELISA kit and the concentration (pg / mL) was converted to IU / mL (IL-2: 1 ng / mL = 16.36 IU / mL). During the first 6 days of the 2 pre-REP runs analyzed, we did not change or add media because the total number of T cells was low early on. However, although the yield of both T5101001 and T5101002 pre-REP TILs was less than 2×10 6, but we still observed a decrease of approximately 50% in IL-2 levels.

[0200] We seeded TILs derived from single tumor fragments in 24-well plates. 10M device, and further cultured them for an additional 8 days without changing / adding medium in the first 6 days. We found that the IL-2 levels in the culture medium samples from T5101001 and T5101002 decreased by about 50% after 6 days, although their expansion processes were obviously different (for T5101001-5×10 6 and T5101001-10×10 6 They are 53.8 and 20.3 times respectively; for T5101002-5×10 6 and T5101002-10×10 6 Thus, T cell growth does not appear to be a determining factor for the decrease in IL-2 concentrations in REP TIL cultures.

[0201] In addition, we studied the pre-REP period IL-2 consumption in 100M devices (same sample set as used for glucose and lactate measurements). In this analysis, donor T5101009 and donor T5101010 had significantly different REP TIL yields (2.2 × 10 6 vs 93×10 6 ), whereas the preparatory REP run showed a comparable IL-2 decline curve. It is worth noting that no media changes / additions were performed for these two donors during the entire preparatory REP phase. The result is that no matter how robustly the T cells expanded, about 20% of the original IL-2 concentration remained at day 14.

[0202] Preparatory REP Program

[0203] Day 0 - Tumor fragmentation and primary TIL culture. Briefly, tumors were dissected into fragments of approximately 2-3 mm in each dimension, while necrotic, hemorrhagic, and lipid deposits were removed. Each TIL with an initial culture volume of 10 mL, 20 mL, 25 mL, 30 mL, 50 mL, or 100 mL was cultured. 10M culture device culture 1, 2, 3, 4 or 5 fragments. For up to 100 fragments in total, one to two with 100mL, 200mL, 250mL, 500mL or 1000mL initial culture volume can be used. 100M culture set. The total prepared REP medium for the entire process can be prepared on day 0 using 500 or 1000 mL of prepared REP basal medium supplemented with 300 IU / mL, 1000 IU / mL, 3000 IU / mL, or 6000 IU / mL IL-2. In one embodiment, the IL-2 concentration is 300 IU / mL. In another embodiment, the IL-2 concentration is 1000 IU / mL. In yet another embodiment, the IL-2 concentration is 3000 IU / mL. In yet another embodiment, the IL-2 concentration is 6000 IU / mL.

[0204] Day 8, 9, 10, or 11 - Add or exchange medium. Warm the prepared REP CM (medium) prepared on Day 0 at room temperature or 37°C before use. If using 10M device or For 100M devices, add or exchange a total volume of 1, 2, or 3 times the initial prepared REP CM volume to each culture device. Return the culture devices to the incubator to continue TIL culture.

[0205] Day 13, 14, 15, 16, or 17 - Harvest preparatory REP TILs. Prepare 100 or 200 mL of harvest solution using Plasma-Lyte A (multiple electrolytes for injection) and human serum albumin (HSA) to achieve a final concentration of 0.5%, 0.7%, 1%, 1.5%, 2%, or 5% HSA solution. Harvest TILs manually. Collect cell suspension and filter through cell strainer. Wash The device was applied twice to ensure that all TILs were collected.

[0206] The cells were centrifuged at 200, 300 or 400 g for 15 or 30 minutes at 4° C. The supernatant was discarded and the cell pellets were resuspended and pooled in Plasma-Lyte A using harvest solution containing HSA. Cell counts were performed using an NC200 automated cell counter and cells were cryopreserved.

[0207] The following culture conditions were used.

[0208] Culture conditions (Ai):

[0209] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0210] Day 8 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0211] Day 13 - Harvest the preparatory REP TILs.

[0212] Culture conditions (A-ii):

[0213] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0214] Day 8 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0215] Day 13 - Harvest the preparatory REP TILs.

[0216] Culture conditions (A-iii):

[0217] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0218] Day 8 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0219] Day 13 - Harvest the preparatory REP TILs.

[0220] Culture conditions (A-iv):

[0221] Day 0 - Initial culture volume 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0222] Day 8 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0223] Day 13 - Harvest the preparatory REP TILs.

[0224] Culture conditions (Av):

[0225] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0226] Day 8 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0227] Day 13 - Harvest the preparatory REP TILs.

[0228] Culture conditions (A-vi):

[0229] Day 0 - Initial culture volume for 10M is 100mL (or 100M is 1000 mL). In other words, the initial culture volume for the first expansion is 100% of the capacity of the cell culture vessel / system.

[0230] Day 8 - The cell culture medium was exchanged with a volume that was 1 times the initial culture volume.

[0231] Day 13 - Harvest the preparatory REP TILs.

[0232] Culture conditions (A-vii):

[0233] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0234] Day 8 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0235] Day 13 - Harvest the preparatory REP TILs.

[0236] Culture conditions (A-viii):

[0237] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0238] Day 8 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0239] Day 13 - Harvest the preparatory REP TILs.

[0240] Culture conditions (A-ix):

[0241] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0242] Day 8 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0243] Day 13 - Harvest the preparatory REP TILs.

[0244] Culture conditions (Ax):

[0245] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0246] Day 8 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0247] Day 13 - Harvest the preparatory REP TILs.

[0248] Culture conditions (A-xi):

[0249] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0250] Day 8 - The cell culture medium was exchanged with a volume twice the initial culture volume.

[0251] Day 13 - Harvest the preparatory REP TILs.

[0252] Culture conditions (A-xii):

[0253] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0254] Day 8 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0255] Day 13 - Harvest the preparatory REP TILs.

[0256] Culture conditions (A-xiii):

[0257] Day 0 - Initial culture volume 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0258] Day 8 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0259] Day 13 - Harvest the preparatory REP TILs.

[0260] Culture conditions (A-xiv):

[0261] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0262] Day 8 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0263] Day 13 - Harvest the preparatory REP TILs.

[0264] Culture conditions (A-xv):

[0265] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0266] Day 8 - The cell culture medium was exchanged with a volume 3 times the initial culture volume.

[0267] Day 13 - Harvest the preparatory REP TILs.

[0268] Culture conditions (Bi):

[0269] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0270] Day 9 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0271] Day 13 - Harvest the preparatory REP TILs.

[0272] Culture conditions (B-ii):

[0273] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0274] Day 9 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0275] Day 13 - Harvest the preparatory REP TILs.

[0276] Culture conditions (B-iii):

[0277] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0278] Day 9 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0279] Day 13 - Harvest the preparatory REP TILs.

[0280] Culture conditions (B-iv):

[0281] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0282] Day 9 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0283] Day 13 - Harvest the preparatory REP TILs.

[0284] Culture conditions (Bv):

[0285] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0286] Day 9 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0287] Day 13 - Harvest the preparatory REP TILs.

[0288] Culture conditions (B-vi):

[0289] Day 0 - Initial culture volume for 10M is 100mL (or 100M is 1000 mL). In other words, the initial culture volume for the first expansion is 100% of the capacity of the cell culture vessel / system.

[0290] Day 9 - The cell culture medium was exchanged with a volume that was 1 times the initial culture volume.

[0291] Day 13 - Harvest the preparatory REP TILs.

[0292] Culture conditions (B-vii):

[0293] Day 0 - Initial culture volume 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0294] Day 9 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0295] Day 13 - Harvest the preparatory REP TILs.

[0296] Culture conditions (B-viii):

[0297] Day 0 - Initial culture volume 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0298] Day 9 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0299] Day 13 - Harvest the preparatory REP TILs.

[0300] Culture conditions (B-ix):

[0301] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0302] Day 9 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0303] Day 13 - Harvest the preparatory REP TILs.

[0304] Culture conditions (Bx):

[0305] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0306] Day 9 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0307] Day 13 - Harvest the preparatory REP TILs.

[0308] Culture conditions (B-xi):

[0309] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0310] Day 9 - The cell culture medium was exchanged with a volume twice the initial culture volume.

[0311] Day 13 - Harvest the preparatory REP TILs.

[0312] Culture conditions (B-xii):

[0313] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0314] Day 9 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0315] Day 13 - Harvest the preparatory REP TILs.

[0316] Culture conditions (B-xiii):

[0317] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0318] Day 9 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0319] Day 13 - Harvest the preparatory REP TILs.

[0320] Culture conditions (B-xiv):

[0321] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0322] Day 9 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0323] Day 13 - Harvest the preparatory REP TILs.

[0324] Culture conditions (B-xv):

[0325] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0326] Day 9 - The cell culture medium was exchanged with a volume 3 times the initial culture volume.

[0327] Day 13 - Harvest the preparatory REP TILs.

[0328] Culture conditions (Ci):

[0329] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0330] Day 10 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0331] Day 13 - Harvest the preparatory REP TILs.

[0332] Culture conditions (C-ii):

[0333] Day 0 - Initial culture volume 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0334] Day 10 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0335] Day 13 - Harvest the preparatory REP TILs.

[0336] Culture conditions (C-iii):

[0337] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0338] Day 10 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0339] Day 13 - Harvest the preparatory REP TILs.

[0340] Culture conditions (C-iv):

[0341] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0342] Day 10 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0343] Day 13 - Harvest the preparatory REP TILs.

[0344] Culture conditions (Cv):

[0345] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0346] Day 10 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0347] Day 13 - Harvest the preparatory REP TILs.

[0348] Culture conditions (C-vi):

[0349] Day 0 - Initial culture volume for 10M is 100mL (or 100M is 1000 mL). In other words, the initial culture volume for the first expansion is 100% of the capacity of the cell culture vessel / system.

[0350] Day 10 - The cell culture medium was exchanged with a volume that was 1 times the initial culture volume.

[0351] Day 13 - Harvest the preparatory REP TILs.

[0352] Culture conditions (C-vii):

[0353] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0354] Day 10 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0355] Day 13 - Harvest the preparatory REP TILs.

[0356] Culture conditions (C-viii):

[0357] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0358] Day 10 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0359] Day 13 - Harvest the preparatory REP TILs.

[0360] Culture conditions (C-ix):

[0361] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0362] Day 10 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0363] Day 13 - Harvest the preparatory REP TILs.

[0364] Culture conditions (Cx):

[0365] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0366] Day 10 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0367] Day 13 - Harvest the preparatory REP TILs.

[0368] Culture conditions (C-xi):

[0369] Day 0 - Initial culture volume 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0370] Day 10 - Cell culture medium is exchanged with a volume twice the initial culture volume.

[0371] Day 13 - Harvest the preparatory REP TILs.

[0372] Culture conditions (C-xii):

[0373] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0374] Day 10 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0375] Day 13 - Harvest the preparatory REP TILs.

[0376] Culture conditions (C-xiii):

[0377] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0378] Day 10 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0379] Day 13 - Harvest the preparatory REP TILs.

[0380] Culture conditions (C-xiv):

[0381] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0382] Day 10 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0383] Day 13 - Harvest the preparatory REP TILs.

[0384] Culture conditions (C-xv):

[0385] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0386] Day 10 - Cell culture medium is exchanged with a volume 3 times the initial culture volume.

[0387] Day 13 - Harvest the preparatory REP TILs.

[0388] Culture conditions (Di):

[0389] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0390] Day 11 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0391] Day 13 - Harvest the preparatory REP TILs.

[0392] Culture conditions (D-ii):

[0393] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0394] Day 11 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0395] Day 13 - Harvest the preparatory REP TILs.

[0396] Culture conditions (D-iii):

[0397] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0398] Day 11 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0399] Day 13 - Harvest the preparatory REP TILs.

[0400] Culture conditions (D-iv):

[0401] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0402] Day 11 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0403] Day 13 - Harvest the preparatory REP TILs.

[0404] Culture conditions (Dv):

[0405] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0406] Day 11 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0407] Day 13 - Harvest the preparatory REP TILs.

[0408] Culture conditions (D-vi):

[0409] Day 0 - Initial culture volume for 10M is 100mL (or 100M is 1000 mL). In other words, the initial culture volume for the first expansion is 100% of the capacity of the cell culture vessel / system.

[0410] Day 11 - The cell culture medium was exchanged with a volume that was 1 times the initial culture volume.

[0411] Day 13 - Harvest the preparatory REP TILs.

[0412] Culture conditions (D-vii):

[0413] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0414] Day 11 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0415] Day 13 - Harvest the preparatory REP TILs.

[0416] Culture conditions (D-viii):

[0417] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0418] Day 11 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0419] Day 13 - Harvest the preparatory REP TILs.

[0420] Culture conditions (D-ix):

[0421] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0422] Day 11 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0423] Day 13 - Harvest the preparatory REP TILs.

[0424] Culture conditions (Dx):

[0425] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0426] Day 11 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0427] Day 13 - Harvest the preparatory REP TILs.

[0428] Culture conditions (D-xi):

[0429] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0430] Day 11 - The cell culture medium was exchanged with a volume twice the initial culture volume.

[0431] Day 13 - Harvest the preparatory REP TILs.

[0432] Culture conditions (D-xii):

[0433] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0434] Day 11 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0435] Day 13 - Harvest the preparatory REP TILs.

[0436] Culture conditions (D-xiii):

[0437] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0438] Day 11 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0439] Day 13 - Harvest the preparatory REP TILs.

[0440] Culture conditions (D-xiv):

[0441] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0442] Day 11 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0443] Day 13 - Harvest the preparatory REP TILs.

[0444] Culture conditions (D-xv):

[0445] Day 0 - Initial culture volume 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0446] Day 11 - The cell culture medium was exchanged with a volume 3 times the initial culture volume.

[0447] Day 13 - Harvest the preparatory REP TILs.

[0448] Culture conditions (Ei):

[0449] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0450] Day 8 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0451] Day 14 - Harvest of preparatory REP TILs.

[0452] Culture conditions (E-ii):

[0453] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0454] Day 8 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0455] Day 14 - Harvest of preparatory REP TILs.

[0456] Culture conditions (E-iii):

[0457] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0458] Day 8 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0459] Day 14 - Harvest of preparatory REP TILs.

[0460] Culture conditions (E-iv):

[0461] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0462] Day 8 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0463] Day 14 - Harvest of preparatory REP TILs.

[0464] Culture conditions (Ev):

[0465] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0466] Day 8 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0467] Day 14 - Harvest of preparatory REP TILs.

[0468] Culture conditions (E-vi):

[0469] Day 0 - Initial culture volume for 10M is 100mL (or 100M is 1000 mL). In other words, the initial culture volume for the first expansion is 100% of the capacity of the cell culture vessel / system.

[0470] Day 8 - The cell culture medium was exchanged with a volume that was 1 times the initial culture volume.

[0471] Day 14 - Harvest of preparatory REP TILs.

[0472] Culture conditions (E-vii):

[0473] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0474] Day 8 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0475] Day 14 - Harvest of preparatory REP TILs.

[0476] Culture conditions (E-viii):

[0477] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0478] Day 8 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0479] Day 14 - Harvest of preparatory REP TILs.

[0480] Culture conditions (E-ix):

[0481] Day 0 - Initial culture volume 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0482] Day 8 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0483] Day 14 - Harvest of preparatory REP TILs.

[0484] Culture conditions (Ex):

[0485] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0486] Day 8 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0487] Day 14 - Harvest of preparatory REP TILs.

[0488] Culture conditions (E-xi):

[0489] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0490] Day 8 - The cell culture medium was exchanged with a volume twice the initial culture volume.

[0491] Day 14 - Harvest the prepared REP TILs.

[0492] Culture conditions (E-xii):

[0493] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0494] Day 8 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0495] Day 14 - Harvest the prepared REP TILs.

[0496] Culture conditions (E-xiii):

[0497] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0498] Day 8 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0499] Day 14 - Harvest the prepared REP TILs.

[0500] Culture conditions (E-xiv):

[0501] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0502] Day 8 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0503] Day 14 - Harvest the prepared REP TILs.

[0504] Culture conditions (E-xv):

[0505] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0506] Day 8 - The cell culture medium was exchanged with a volume 3 times the initial culture volume.

[0507] Day 14 - Harvest the prepared REP TILs.

[0508] Culture conditions (Fi):

[0509] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0510] Day 9 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0511] Day 14 - Harvest the prepared REP TILs.

[0512] Culture conditions (F-ii):

[0513] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0514] Day 9 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0515] Day 14 - Harvest the prepared REP TILs.

[0516] Culture conditions (F-iii):

[0517] Day 0 - Initial culture volume 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0518] Day 9 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0519] Day 14 - Harvest the prepared REP TILs.

[0520] Culture conditions (F-iv):

[0521] Day 0 - Initial culture volume 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0522] Day 9 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0523] Day 14 - Harvest the prepared REP TILs.

[0524] Culture conditions (Fv):

[0525] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0526] Day 9 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0527] Day 14 - Harvest the prepared REP TILs.

[0528] Culture conditions (F-vi):

[0529] Day 0 - Initial culture volume for 10M is 100mL (or 100M is 1000 mL). In other words, the initial culture volume for the first expansion is 100% of the capacity of the cell culture vessel / system.

[0530] Day 9 - The cell culture medium was exchanged with a volume that was 1 times the initial culture volume.

[0531] Day 14 - Harvest the prepared REP TILs.

[0532] Culture conditions (F-vii):

[0533] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0534] Day 9 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0535] Day 14 - Harvest the prepared REP TILs.

[0536] Culture conditions (F-viii):

[0537] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0538] Day 9 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0539] Day 14 - Harvest the prepared REP TILs.

[0540] Culture conditions (F-ix):

[0541] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0542] Day 9 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0543] Day 14 - Harvest the prepared REP TILs.

[0544] Culture conditions (Fx):

[0545] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0546] Day 9 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0547] Day 14 - Harvest the prepared REP TILs.

[0548] Culture conditions (F-xi):

[0549] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0550] Day 9 - The cell culture medium was exchanged with a volume twice the initial culture volume.

[0551] Day 14 - Harvest the prepared REP TILs.

[0552] Culture conditions (F-xii):

[0553] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0554] Day 9 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0555] Day 14 - Harvest the prepared REP TILs.

[0556] Culture conditions (F-xiii):

[0557] Day 0 - Initial culture volume 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0558] Day 9 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0559] Day 14 - Harvest the prepared REP TILs.

[0560] Culture conditions (F-xiv):

[0561] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0562] Day 9 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0563] Day 14 - Harvest the prepared REP TILs.

[0564] Culture conditions (F-xv):

[0565] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0566] Day 9 - The cell culture medium was exchanged with a volume 3 times the initial culture volume.

[0567] Day 14 - Harvest the prepared REP TILs.

[0568] Culture conditions (Gi):

[0569] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0570] Day 10 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0571] Day 14 - Harvest the prepared REP TILs.

[0572] Culture conditions (G-ii):

[0573] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0574] Day 10 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0575] Day 14 - Harvest the prepared REP TILs.

[0576] Culture conditions (G-iii):

[0577] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0578] Day 10 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0579] Day 14 - Harvest the prepared REP TILs.

[0580] Culture conditions (G-iv):

[0581] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0582] Day 10 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0583] Day 14 - Harvest the prepared REP TILs.

[0584] Culture conditions (Gv):

[0585] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0586] Day 10 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0587] Day 14 - Harvest the prepared REP TILs.

[0588] Culture conditions (G-vi):

[0589] Day 0 - Initial culture volume for 10M is 100mL (or 100M is 1000 mL). In other words, the initial culture volume for the first expansion is 100% of the capacity of the cell culture vessel / system.

[0590] Day 10 - The cell culture medium was exchanged with a volume that was 1 times the initial culture volume.

[0591] Day 14 - Harvest the prepared REP TILs.

[0592] Culture conditions (G-vii):

[0593] Day 0 - Initial culture volume 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0594] Day 10 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0595] Day 14 - Harvest the prepared REP TILs.

[0596] Culture conditions (G-viii):

[0597] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0598] Day 10 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0599] Day 14 - Harvest the prepared REP TILs.

[0600] Culture conditions (G-ix):

[0601] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0602] Day 10 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0603] Day 14 - Harvest the prepared REP TILs.

[0604] Culture conditions (Gx):

[0605] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0606] Day 10 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0607] Day 14 - Harvest the prepared REP TILs.

[0608] Culture conditions (G-xi):

[0609] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0610] Day 10 - Cell culture medium is exchanged with a volume twice the initial culture volume.

[0611] Day 14 - Harvest the prepared REP TILs.

[0612] Culture conditions (G-xii):

[0613] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0614] Day 10 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0615] Day 14 - Harvest the prepared REP TILs.

[0616] Culture conditions (G-xiii):

[0617] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0618] Day 10 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0619] Day 14 - Harvest the prepared REP TILs.

[0620] Culture conditions (G-xiv):

[0621] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0622] Day 10 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0623] Day 14 - Harvest the prepared REP TILs.

[0624] Culture conditions (G-xv):

[0625] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0626] Day 10 - Cell culture medium is exchanged with a volume 3 times the initial culture volume.

[0627] Day 14 - Harvest the prepared REP TILs.

[0628] Culture conditions (Hi):

[0629] Day 0 - Initial culture volume 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0630] Day 11 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0631] Day 14 - Harvest the prepared REP TILs.

[0632] Culture conditions (H-ii):

[0633] Day 0 - Initial culture volume 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0634] Day 11 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0635] Day 14 - Harvest the prepared REP TILs.

[0636] Culture conditions (H-iii):

[0637] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0638] Day 11 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0639] Day 14 - Harvest the prepared REP TILs.

[0640] Culture conditions (H-iv):

[0641] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0642] Day 11 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0643] Day 14 - Harvest the prepared REP TILs.

[0644] Culture conditions (Hv):

[0645] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0646] Day 11 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0647] Day 14 - Harvest the prepared REP TILs.

[0648] Culture conditions (H-vi):

[0649] Day 0 - Initial culture volume for 10M is 100mL (or 100M is 1000 mL). In other words, the initial culture volume for the first expansion is 100% of the capacity of the cell culture vessel / system.

[0650] Day 11 - The cell culture medium was exchanged with a volume that was 1 times the initial culture volume.

[0651] Day 14 - Harvest the prepared REP TILs.

[0652] Culture conditions (H-vii):

[0653] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0654] Day 11 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0655] Day 14 - Harvest the prepared REP TILs.

[0656] Culture conditions (H-viii):

[0657] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0658] Day 11 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0659] Day 14 - Harvest the prepared REP TILs.

[0660] Culture conditions (H-ix):

[0661] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0662] Day 11 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0663] Day 14 - Harvest the prepared REP TILs.

[0664] Culture conditions (Hx):

[0665] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0666] Day 11 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0667] Day 14 - Harvest the prepared REP TILs.

[0668] Culture conditions (H-xi):

[0669] Day 0 - Initial culture volume 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0670] Day 11 - The cell culture medium was exchanged with a volume twice the initial culture volume.

[0671] Day 14 - Harvest the prepared REP TILs.

[0672] Culture conditions (H-xii):

[0673] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0674] Day 11 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0675] Day 14 - Harvest the prepared REP TILs.

[0676] Culture conditions (H-xiii):

[0677] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0678] Day 11 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0679] Day 14 - Harvest the prepared REP TILs.

[0680] Culture conditions (H-xiv):

[0681] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0682] Day 11 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0683] Day 14 - Harvest the prepared REP TILs.

[0684] Culture conditions (H-xv):

[0685] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0686] Day 11 - The cell culture medium was exchanged with a volume 3 times the initial culture volume.

[0687] Day 14 - Harvest the prepared REP TILs.

[0688] Culture conditions (Ii):

[0689] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0690] Day 8 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0691] Day 15 - Harvest the prepared REP TILs.

[0692] Culture conditions (I-ii):

[0693] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0694] Day 8 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0695] Day 15 - Harvest the prepared REP TILs.

[0696] Culture conditions (I-iii):

[0697] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0698] Day 8 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0699] Day 15 - Harvest the prepared REP TILs.

[0700] Culture conditions (I-iv):

[0701] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0702] Day 8 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0703] Day 15 - Harvest the prepared REP TILs.

[0704] Culture conditions (IV):

[0705] Day 0 - Initial culture volume 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0706] Day 8 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0707] Day 15 - Harvest the prepared REP TILs.

[0708] Culture conditions (I-vi):

[0709] Day 0 - Initial culture volume for 10M is 100mL (or 100M is 1000 mL). In other words, the initial culture volume for the first expansion is 100% of the capacity of the cell culture vessel / system.

[0710] Day 8 - The cell culture medium was exchanged with a volume that was 1 times the initial culture volume.

[0711] Day 15 - Harvest the prepared REP TILs.

[0712] Culture conditions (I-vii):

[0713] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0714] Day 8 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0715] Day 15 - Harvest the prepared REP TILs.

[0716] Culture conditions (I-viii):

[0717] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0718] Day 8 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0719] Day 15 - Harvest the prepared REP TILs.

[0720] Culture conditions (I-ix):

[0721] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0722] Day 8 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0723] Day 15 - Harvest the prepared REP TILs.

[0724] Culture conditions (Ix):

[0725] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0726] Day 8 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0727] Day 15 - Harvest the prepared REP TILs.

[0728] Culture conditions (I-xi):

[0729] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0730] Day 8 - The cell culture medium was exchanged with a volume twice the initial culture volume.

[0731] Day 15 - Harvest the prepared REP TILs.

[0732] Culture conditions (I-xii):

[0733] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0734] Day 8 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0735] Day 15 - Harvest the prepared REP TILs.

[0736] Culture conditions (I-xiii):

[0737] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0738] Day 8 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0739] Day 15 - Harvest the prepared REP TILs.

[0740] Culture conditions (I-xiv):

[0741] Day 0 - Initial culture volume 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0742] Day 8 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0743] Day 15 - Harvest the prepared REP TILs.

[0744] Culture conditions (I-xV):

[0745] Day 0 - Initial culture volume 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0746] Day 8 - The cell culture medium was exchanged with a volume 3 times the initial culture volume.

[0747] Day 15 - Harvest the prepared REP TILs.

[0748] Culture conditions (Ji):

[0749] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0750] Day 9 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0751] Day 15 - Harvest the prepared REP TILs.

[0752] Culture conditions (J-ii):

[0753] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0754] Day 9 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0755] Day 15 - Harvest the prepared REP TILs.

[0756] Culture conditions (J-iii):

[0757] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0758] Day 9 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0759] Day 15 - Harvest the prepared REP TILs.

[0760] Culture conditions (J-iv):

[0761] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0762] Day 9 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0763] Day 15 - Harvest the prepared REP TILs.

[0764] Culture conditions (Jv):

[0765] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0766] Day 9 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0767] Day 15 - Harvest the prepared REP TILs.

[0768] Culture conditions (J-vi):

[0769] Day 0 - Initial culture volume for 10M is 100mL (or 100M is 1000 mL). In other words, the initial culture volume for the first expansion is 100% of the capacity of the cell culture vessel / system.

[0770] Day 9 - The cell culture medium was exchanged with a volume that was 1 times the initial culture volume.

[0771] Day 15 - Harvest the prepared REP TILs.

[0772] Culture conditions (J-vii):

[0773] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0774] Day 9 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0775] Day 15 - Harvest the prepared REP TILs.

[0776] Culture conditions (J-viii):

[0777] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0778] Day 9 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0779] Day 15 - Harvest the prepared REP TILs.

[0780] Culture conditions (J-ix):

[0781] Day 0 - Initial culture volume 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0782] Day 9 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0783] Day 15 - Harvest the prepared REP TILs.

[0784] Culture conditions (Jx):

[0785] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0786] Day 9 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0787] Day 15 - Harvest the prepared REP TILs.

[0788] Culture conditions (J-xi):

[0789] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0790] Day 9 - The cell culture medium was exchanged with a volume twice the initial culture volume.

[0791] Day 15 - Harvest the prepared REP TILs.

[0792] Culture conditions (J-xii):

[0793] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0794] Day 9 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0795] Day 15 - Harvest the prepared REP TILs.

[0796] Culture conditions (J-xiii):

[0797] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0798] Day 9 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0799] Day 15 - Harvest the prepared REP TILs.

[0800] Culture conditions (J-xiv):

[0801] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0802] Day 9 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0803] Day 15 - Harvest the prepared REP TILs.

[0804] Culture conditions (J-xv):

[0805] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0806] Day 9 - The cell culture medium was exchanged with a volume 3 times the initial culture volume.

[0807] Day 15 - Harvest the prepared REP TILs.

[0808] Culture conditions (Ki):

[0809] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0810] Day 10 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0811] Day 15 - Harvest the prepared REP TILs.

[0812] Culture conditions (K-ii):

[0813] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0814] Day 10 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0815] Day 15 - Harvest the prepared REP TILs.

[0816] Culture conditions (K-iii):

[0817] Day 0 - Initial culture volume 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0818] Day 10 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0819] Day 15 - Harvest the prepared REP TILs.

[0820] Culture conditions (K-iv):

[0821] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0822] Day 10 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0823] Day 15 - Harvest the prepared REP TILs.

[0824] Culture conditions (Kv):

[0825] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0826] Day 10 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0827] Day 15 - Harvest the prepared REP TILs.

[0828] Culture conditions (K-vi):

[0829] Day 0 - Initial culture volume for 10M is 100mL (or 100M is 1000 mL). In other words, the initial culture volume for the first expansion is 100% of the capacity of the cell culture vessel / system.

[0830] Day 10 - The cell culture medium was exchanged with a volume that was 1 times the initial culture volume.

[0831] Day 15 - Harvest the prepared REP TILs.

[0832] Culture conditions (K-vii):

[0833] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0834] Day 10 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0835] Day 15 - Harvest the prepared REP TILs.

[0836] Culture conditions (K-viii):

[0837] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0838] Day 10 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0839] Day 15 - Harvest the prepared REP TILs.

[0840] Culture conditions (K-ix):

[0841] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0842] Day 10 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0843] Day 15 - Harvest the prepared REP TILs.

[0844] Culture conditions (Kx):

[0845] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0846] Day 10 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0847] Day 15 - Harvest the prepared REP TILs.

[0848] Culture conditions (K-xi):

[0849] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0850] Day 10 - Cell culture medium is exchanged with a volume twice the initial culture volume.

[0851] Day 15 - Harvest the prepared REP TILs.

[0852] Culture conditions (K-xii):

[0853] Day 0 - Initial culture volume 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0854] Day 10 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0855] Day 15 - Harvest the prepared REP TILs.

[0856] Culture conditions (K-xiii):

[0857] Day 0 - Initial culture volume 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0858] Day 10 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0859] Day 15 - Harvest the prepared REP TILs.

[0860] Culture conditions (K-xiv):

[0861] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0862] Day 10 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0863] Day 15 - Harvest the prepared REP TILs.

[0864] Culture conditions (K-xv):

[0865] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0866] Day 10 - Cell culture medium is exchanged with a volume 3 times the initial culture volume.

[0867] Day 15 - Harvest the prepared REP TILs.

[0868] Culture conditions (Li):

[0869] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0870] Day 11 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0871] Day 15 - Harvest the prepared REP TILs.

[0872] Culture conditions (L-ii):

[0873] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0874] Day 11 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0875] Day 15 - Harvest the prepared REP TILs.

[0876] Culture conditions (L-iii):

[0877] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0878] Day 11 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0879] Day 15 - Harvest the prepared REP TILs.

[0880] Culture conditions (L-iv):

[0881] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0882] Day 11 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0883] Day 15 - Harvest the prepared REP TILs.

[0884] Culture conditions (Lv):

[0885] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0886] Day 11 - Cell culture medium was added or exchanged at a volume equal to 1 times the initial culture volume.

[0887] Day 15 - Harvest the prepared REP TILs.

[0888] Culture conditions (L-vi):

[0889] Day 0 - Initial culture volume for 10M is 100mL (or 100M is 1000 mL). In other words, the initial culture volume for the first expansion is 100% of the capacity of the cell culture vessel / system.

[0890] Day 11 - The cell culture medium was exchanged with a volume that was 1 times the initial culture volume.

[0891] Day 15 - Harvest the prepared REP TILs.

[0892] Culture conditions (L-vii):

[0893] Day 0 - Initial culture volume 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0894] Day 11 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0895] Day 15 - Harvest the prepared REP TILs.

[0896] Culture conditions (L-viii):

[0897] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0898] Day 11 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0899] Day 15 - Harvest the prepared REP TILs.

[0900] Culture conditions (L-ix):

[0901] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0902] Day 11 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0903] Day 15 - Harvest the prepared REP TILs.

[0904] Culture conditions (Lx):

[0905] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0906] Day 11 - Cell culture medium was added or exchanged at a volume twice the initial culture volume.

[0907] Day 15 - Harvest the prepared REP TILs.

[0908] Culture conditions (L-xi):

[0909] Day 0 - Initial culture volume for 10M is 50mL (or 100M is 500 mL). In other words, the initial culture volume for the first expansion is 50% of the capacity of the cell culture vessel / system.

[0910] Day 11 - The cell culture medium was exchanged with a volume twice the initial culture volume.

[0911] Day 15 - Harvest the prepared REP TILs.

[0912] Culture conditions (L-xii):

[0913] Day 0 - Initial culture volume for 10M is 10mL (or 100M is 100 mL). In other words, the initial culture volume for the first expansion is 10% of the capacity of the cell culture vessel / system.

[0914] Day 11 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0915] Day 15 - Harvest the prepared REP TILs.

[0916] Culture conditions (L-xiii):

[0917] Day 0 - Initial culture volume for 10M is 20mL (or 100M is 200 mL). In other words, the initial culture volume for the first expansion is 20% of the capacity of the cell culture vessel / system.

[0918] Day 11 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0919] Day 15 - Harvest the prepared REP TILs.

[0920] Culture conditions (L-xiv):

[0921] Day 0 - Initial culture volume for 10M is 25mL (or 100M is 250 mL). In other words, the initial culture volume for the first expansion is 25% of the capacity of the cell culture vessel / system.

[0922] Day 11 - Cell culture medium was added or exchanged at a volume 3 times the initial culture volume.

[0923] Day 15 - Harvest the prepared REP TILs.

[0924] Culture conditions (L-xv):

[0925] Day 0 - Initial culture volume for 10M is 30mL (or 100M is 300 mL). In other words, the initial culture volume for the first expansion is 30% of the capacity of the cell culture vessel / system.

[0926] Day 11 - The cell culture medium was exchanged with a volume 3 times the initial culture volume.

[0927] Day 15 - Harvest the prepared REP TILs.

[0928] Other suitable culture conditions may also be used.

[0929] Success rate before and after optimization

[0930] Prior to optimization, the success rate of REP TIL production was low, with an average yield of 3.10 × 10 6 cells / fragments (Table 1). Full-scale culture was performed in a 100M device, which produced 16.29×10 6 The average yield of cells / fragments was (Table 2). Thus, our optimized method has resulted in a significantly higher yield of harvested REP TILs than before optimization (P = 0.00125; n = 12 before optimization run and n = 8 after optimization run) (Table 2).

[0931] Table 1 Yields of REP cultures prepared before optimization

[0932]

[0933] SD, standard deviation; CI = confidence interval.

[0934] Table 2 Yields of REP cultures prepared after optimization

[0935]

[0936] SD, standard deviation; CI = confidence interval.

[0937] Evaluation of glucose and lactate concentrations in standardized preparatory REP protocols

[0938] To verify that the media additions in the standardized pre-REP protocol were adequate for the process, we collected supernatants from seven runs (T5101014-T5101018, T5101021, and T5101022) at days 0, 6, 10, and 14 and evaluated final TIL yield, glucose concentration, and lactate concentration. By day 6 and thereafter, glucose and lactate levels changed proportionally with the extent of TIL expansion ( Figure 1 However, glucose levels remained high at harvest (7.69 ± 2.86 mM; 95% CI, 5.05-10.33 mM; n = 7), sufficient to support T cell growth (Table 3). Importantly, lactate levels (6.30 ± 3.92 mM; 95% CI, 2.67-9.93 mM; n = 7) remained well below 20 mM, at which CD8 + Killer T cells show reduced proliferation, viability and function 14 In conclusion, our results demonstrate that an optimized preparative REP process can maintain glucose and lactate levels within a range that supports TIL migration and expansion.

[0939] Table 3 Summary of the number of tumor fragments inoculated, glucose and lactate levels in culture after the standardized REP protocol, and TIL yield

[0940]

[0941] SD, standard deviation; CI = confidence interval.

[0942] Preparing for REP TIL characterization

[0943] As expected, prepared REP TILs expanded under optimized conditions had high viability and a high percentage of CD3 + The average viability of REP TILs was 93.68% ± 2.48% (n = 8). + The average percentage of cells was 89.43%±5.31% (n=8).

[0944] CD8 in the prepared REP TIL product + The proportion of cells varied by donor, and the average percentage (37.35%) was similar to other NSCLC-prepared REP TIL products. 3 The prepared REP material had only low percentages of NK cells, B cells, myeloid cells, and epithelial cells. The percentages of NK cells, B cells, myeloid cells, and epithelial cells were 7.74% ± 4.87%, 0.118% ± 0.117%, 0.034% ± 0.032%, and 0.074% ± 0.137%, respectively (n = 8; Figure 2 and Table 4).

[0945] Table 4 Summary of viability (%) and lineage distribution (%) of prepared REP TILs harvested after standardized protocol

[0946] Sample ID Vitality <![CDATA[CD3 + ]]> <![CDATA[CD3 + / CD4 + ]]> <![CDATA[CD3 + / CD8 + ]]> NK B Myeloid Epithelial T5101014 92.1 83.00 33.20 57.10 11.70 0.340 0.027 0.025 T5101015 94.3 85.90 58.30 39.00 10.70 0.140 0.035 0.070 T5101016 92.4 91.20 57.60 38.90 5.86 0.230 0.033 0.014 T5101017 90.4 81.80 70.90 17.30 16.50 0.015 0.110 0.029 T5101018 95.7 91.10 66.90 30.90 6.20 0.002 0.019 0.023 T5101021 91.2 93.20 71.70 19.50 3.58 0.120 0.019 0.019 T5101022 96.6 92.20 70.50 27.70 5.77 0.062 0.014 0.410 T5101024 96.7 97.00 20.20 68.40 1.58 0.035 0.011 0.004 Mean 93.68 89.43 56.16 37.35 7.74 0.118 0.034 0.074 SD 2.48 5.31 19.30 17.79 4.87 0.117 0.032 0.137 95% CI lower limit 91.60 84.99 40.03 22.48 3.66 0.020 0.007 -0.040 95% CI upper limit 95.75 93.86 72.30 52.22 11.81 0.220 0.060 0.189

[0947] SD, standard deviation; CI = confidence interval; CD3 + / CD4 + , CD3 + CD4 + The percentage of cells;

[0948] CD3 + / CD8 + , CD3 + CD8 + The percentage of cells.

[0949] We also extensively analyzed the phenotype of our primed REP TILs by examining the expression of different activation / inhibition markers and T cell subset distribution. The data showed that these primed REP TILs were activated, with high expression of CD27 and CD28, and a positive frequency of CD4 + Among the preparatory REP TILs, the percentages were 37.94%±7.17% and 94.51%±4.72% (n=8, Figure 3 , Table 5), and in CD8 + Among the preparatory REP TILs, the percentages were 34.45% ± 9.62% and 57.66% ± 19.19%, respectively (n = 8; Figure 4 , Table 7). Different inhibitory markers in CD4 + and CD8 + Preparatory REP T cells express CD4 + LAG-3 expression was lowest on preparatory REP T cells, with a positive frequency of 10.07% ± 3.23% (n = 8; Figure 3 , Table 5). PD-1 in CD4 + and CD8 + Moderate expression on primed REP T cells. + and CD8 + The frequencies of PD-1 positive in REP T cells were 57.43% ± 19.58% and 34.31% ± 21.67%, respectively. + TIM-3 is highly expressed on the prepared REP TIL. + In the prepared REP T cells, it was 53.50%±16.12% (n=8, Figure 3 , Table 5) and in CD8 +In primed REP T cells, it was 71.93% ± 17.85% (n = 8; Figure 4 , Table 7).

[0950] A favorable trait of our prepared REP TILs is the presence of CD4 + and CD8 + Preparing for REP TIL CM High ratio and T EM The ratio is reduced. CM The percentage of CD4 + Among the REP TILs, it was 66.28% ± 12.87%, and in CD8 + Among the preparatory REP TILs, it was 59.04% ± 13.47%. EM The percentage of CD4 + In the preparatory REP TIL, it was 30.98% ± 13.25% (n = 8; Figure 3 , Table 6) and in CD8 + In the preparatory REP TIL, it was 27.66% ± 11.59% (n = 8; Figure 4 , Table 8). In addition, T EFF Minimum proportion of subpopulations (in CD4 + Cells and CD8 + In the 44 samples of T cells, the percentages were 0.26%±0.19% and 4.27%±3.85% respectively; n=8). N / T SCM The percentage of subpopulations was still high in the harvested product: in CD4 + 2.49%±2.28% (n=8) of REP TILs and 2.49%±2.28% (n=8) of CD8 + Among the REP TILs, 9.04% ± 8.65% (n = 8) ( Figure 3 , Table 6; and Figure 4 , Table 8), suggesting a significant early memory TIL phenotype. This is extremely important because the clinical benefit of TIL therapy depends greatly on the specific quality of the TIL product generated from the prepared REP TILs. In summary, we have shown here a method for generating prepared REP TILs in an efficient and timely manner that produces a high yield and favorable TIL phenotype suggestive of successful REP and associated with clinical efficacy.

[0951] Table 5CD4 + Positive frequency of activation / inhibitory surface markers in REP TIL preparation (%)

[0952] Sample ID 4-1BB CD27 CD28 LAG-3 PD-1 TIM-3 T5101014 1.67 38.50 84.20 5.38 28.20 72.20 T5101015 133 42.10 96.20 8.29 73.50 64.10 T5101016 2.27 32.00 96.10 15.30 52.00 41.00 T5101017 0.32 34.30 99.10 7.99 78.60 47.60 T5101018 0.65 40.80 97.90 13.10 43.90 70.30 T5101021 0.98 25.60 95.00 10.70 66.90 49.60 T5101022 3.05 41.20 96.10 8.08 78.40 24.50 T5101024 15.4 49.00 91.50 11.70 37.90 58.70 Mean 3.21 37.94 94.51 10.07 57.43 53.50 SD 5.00 7.17 4.72 3.23 19.58 16.12 95% CI lower limit -0.97 31.95 90.56 7.37 41.05 40.02 95% CI upper limit 7.39 43.93 98.46 12.77 73.80 66.98

[0953] SD, standard deviation; CI = confidence interval.

[0954] Table 6CD4 + Frequency of subpopulations in REP TILs (%)

[0955]

[0956]

[0957] SD, standard deviation; CI = confidence interval; T N , naive T cells; T SCM , stem cell memory T cells; T CM , central memory T cells; T EM , effector memory T cells; T EFF , effector T cells.

[0958] Table 7CD8 + Positive frequency of activation / inhibitory surface markers in REP TIL preparation (%)

[0959] Sample ID 4-1BB CD27 CD28 LAG-3 PD-1 TIM-3 T5101014 2.50 44.40 38.00 31.90 11.20 83.40 T5101015 2.76 22.80 69.40 13.10 7.77 44.50 T5101016 3.10 37.40 49.40 29.40 38.80 73.00 T5101017 2.01 23.10 33.40 56.30 60.70 90.20 T5101018 4.29 37.50 74.40 44.40 30.10 89.20 T5101021 137 48.60 67.80 18.70 63.30 53.30 T5101022 7.57 35.40 85.90 15.10 46.40 57.40 T5101024 5.29 26.40 43.00 13.90 16.20 84.40 Mean 3.61 34.45 57.66 27.85 34.31 71.93 SD 2.03 9.62 19.19 15.86 21.67 17.85 95% CI lower limit 1.92 26.41 41.62 14.59 16.19 57.00 95% CI upper limit 5.31 42.49 73.70 41.11 52.43 86.85

[0960] SD, standard deviation; CI = confidence interval.

[0961] Table 8CD8 + Frequency of subpopulations in REP TILs (%)

[0962] Sample ID <![CDATA[T N / T SCM ]]> <![CDATA[T CM ]]> <![CDATA[T EM ]]> <![CDATA[T EFF ]]> T5101014 15.70 66.10 16.20 2.07 T5101015 7.89 63.30 25.10 3.71 T5101016 27.50 42.60 17.00 12.90 T5101017 6.85 33.00 53.70 6.41 T5101018 3.59 66.10 29.30 0.99 T5101021 237 67.30 28.40 1.93 T5101022 1.85 69.20 25.50 3.43 T5101024 6.55 64.70 26.10 2.72 Mean 9.04 59.04 27.66 4.27 SD 8.65 13.47 11.59 3.85 95% CI lower limit 1.81 47.78 17.97 1.06 95% CI upper limit 16.27 70.30 37.35 7.49

[0963] SD, standard deviation; CI = confidence interval; T N , naive T cells; T SCM , stem cell memory T cells; T CM , central memory T cells; T EM , effector memory T cells; T EFF , effector T cells.

[0964] in conclusion

[0965] We have optimized a REP-prepared TIL culture method that produces a high proportion of T CM Together, these studies can be used to support the preparation of REP clinical manufacturing and subsequent TIL experiments.

[0966] References

[0967] 1. Jansen, CS et al. An intra-tumoral niche maintains and differentiates stem-like CD8T cells. Nature 576, 465-470 (2019).

[0968] 2. Jin, J. et al. Simplified method of the growth of human tumorinfiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J Immunother 35, 283-292 (2012).

[0969] 3. Creelan, BC et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med 27, 1410-1418 (2021).

[0970] 4. Rosenberg, SA et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17, 4550-4557 (2011).

[0971] 5. Ando, ​​M., Ito, M., Srirat, T., Kondo, T., and Yoshimura, A. Memory T cell, exhaustion, and tumor immunity. Immunol Med 43, 1-9 (2020).

[0972] 6. Rosenberg, SA, Spiess, P. and Lafreniere, RA New approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318-1321 (1986).

[0973] 7. Huang, J. et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 28, 258-267 (2005). 8. Powell, DJ, Dudley, ME, Robbins, PF and Rosenberg, SA Transition of late-stage effector T cells to CD27+CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105, 241-250 (2005).

[0974] 9. Dudley, ME, Wunderlich, JR, Shelton, TE, Even, J. & Rosenberg, SA Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26, 332-342 (2003).

[0975] 10. Wu, R. et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 18, 160-175 (2012).

[0976] 11. Zhou, J., Dudley, ME, Rosenberg, SA and Robbins, P.F. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 28, 53-62 (2005).

[0977] 12. Tran, KQ et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 31, 742-751 (2008).

[0978] 13. Qiqiu, D. et al. High cell density provides potent survival signals forresting T-cells. Cell Mol Biol (Noisy-le-grand) 46, 163-174 (2000).

[0979] 14. Fischer, K. et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109, 3812-3819 (2007).

[0980] 15. Ghaffari, S. et al. Optimizing interleukin-2 concentration, seeding density and bead-to-cell ratio of T-cell expansion for adoptive immunotherapy. BMC Immunol 22, 43 (2021).

[0981] Example 2: Comparison of TILs generated from conventional REP or feeder-free TransAct REP protocols at small scale

[0982] Conventionally, TILs are grown from single tumor fragments in the wells of 24-well plates in the presence of high-dose IL-2, selected for tumor reactivity and subsequently rapidly expanded. 6 Even if products from this approach are clinically effective, TIL production is challenging because conventional TIL production methods are assayed for specific tumor recognition and typically take 6-8 weeks, which results in TIL exhaustion in vitro and short persistence in vivo. 7,8 Tumor responsiveness selection also results in a lower success rate in generating TILs, leading to a patient dropout rate of more than 50% for TIL-based therapies. 9 , which greatly limits its clinical application 10 An alternative "young" TIL approach has been developed using whole tumor tissue in tissue culture flasks and gas-permeable bags that favors the generation of TILs with attributes associated with improved in vivo persistence, such as long telomeres and increased expression of CD27 and CD28. 11,12 .

[0983] The REP protocol used here is a feeder-free method that is different from the conventional TIL REP protocol, in which irradiated PBMCs and anti-CD3 (OKT3) antibodies are used for expansion. The feeder-free REP process can improve product titer and safety and reduce manufacturing costs. We have compared small-scale TILs using the conventional REP protocol and from the feeder-free TransAct REP process.

[0984] TIL expansion in TransAct REP versus conventional REP

[0985] Using prepared REPTIL from 12 individual donors, we found that the average expansion fold of TILs expanded using the TransAct REP protocol was 389.3±138.8 (Table 9), which is comparable to the conventional REP protocol. This suggests that the TransAct REP protocol can generate sufficient TILs to meet the clinical target dose requirements.

[0986] Table 9 TIL expansion fold using conventional REP or TransAct REP

[0987]

[0988] *Starting number of REP TIL cells on day 0: micro = 0.1 × 10 6 ; Medium = 0.5 × 10 6 ; SD, standard deviation.

[0989] Viability and T cell subtypes of TransAct REP vs. conventional REP

[0990] TransAct REP TILs show consistent CD8 + The proportion of T cells increased significantly ( Figure 5 and Table 10).

[0991] Comparison of T cell phenotypes and inhibitory / activation cell surface markers from TransAct REP or conventional REP

[0992] For TransAct REPTIL, CD4 + Population and CD8 + The percentage of cells showing an early memory phenotype was significantly increased ( Figure 6 , Figure 7 and Table 10), while more differentiated effector T cells (T EM , T EFF ) is reduced by a percentage of ( Figure 6 and Table 10). These TIL characteristics have been shown to be associated with favorable outcomes in TIL adoptive cell therapy 4 .

[0993] The expression of immune checkpoint (inhibitory) and activation cell surface markers of REPTIL was analyzed ( Figure 7 and Table 10). Compared with conventional REPTIL, TransAct REPTIL had a + Subpopulations and CD8 + Both subpopulations had elevated CD27 + The percentage of cells with reduced expression of the exhaustion marker PD-1 CD4 +T cells and CD8 + This further supports the early memory phenotype of TransAct REPTIL.

[0994] Table 10 Summary of the percentages of T cell subtypes and phenotypic markers of TILs expanded by conventional or TransAct REP

[0995]

[0996] *Values ​​are shown as mean percentage ± standard deviation. # Statistical significance was determined by paired t-test; n = 12. CD45 + / CD3 + , CD45 + CD3 + Percentage of cells; CD4+ or CD8 + / T N / SCM , CD4 + cells or CD8 + T cells N Subgroups and T SCM Total percentage of subsets; other subsets and inhibitory / activation markers are also included as CD4 + or CD8 + The percentage in is given; T N , naive T cells; T SCM , stem cell memory T cells; T CM , central memory T cells; T EM , effector memory T cells; T EFF , effector T cells.

[0997] Table 11 shows T cell subsets from another experiment.

[0998] Table 11

[0999] T cell subtypes irPBMC (mean%, range) Method of the present invention (average%, range) p-value <![CDATA[Live / CD3 + > 90(85.6-92.4) 96.1(92.8-98.5) 0.000748 <![CDATA[CD3 + / CD4 + ]]> 91.4(72.6-99) 58.1(10.3-95.7) 0.003454 <![CDATA[CD3 + / CD8 + ]]> 7(0.36-22.4) 36.9(3.27-88.4) 0.005022 <![CDATA[CD4 / T N ]]> 0.1(0.013-0.22) 1.6(0.26-5.44) 0.015843 <![CDATA[CD4 / T N / T SCM ]]> 0.1(0.013-0.22) 1.6(0.26-5.44) 0.015883 <![CDATA[CD4 / T CM ]]> 55(35.3-82.1) 67.3(50.7-87.4) 0.038322 <![CDATA[CD4 / T EM ]]> 44.9(17.8-64.6) 30.6(11.2_48.9) 0.027267 <![CDATA[CD4 / T EFF ]]> 0(0.00667-0.063) 0.5(0.13-1.27) 0.003641 <![CDATA[CD8 / T N ]]> 0.9(0-3.93) 12.2(0.79-28.1) 0.004956 <![CDATA[CD8 / T N / T SCM ]]> 0.9(0-3.83) 12.1(0.78-27.8) 0.004947 <![CDATA[CD8 / T CM ]]> 27.2(4.51-51.2) 54.3(28.6-82.3) 0.002427 <![CDATA[CD8 / T EM ]]> 71.1(48.4-95.5) 28.7(11.8-60.7) 2.17E-05 <![CDATA[CD8 / T EFF ]]> 0.8(0_4.34) 4.8(0.4-18.2) 0.05756 <![CDATA[CD4 / 4-1BB + ]]> 5.4(0.6-27.2) 1.9(0.23-5.71) 0.195645 <![CDATA[CD4 / CD27 + ]]> 18.6(10.5-37.2) 29(10.3-50.5) 0.043882 <![CDATA[CD4 / CD28 + ]]> 96.3(86.5-99.3) 95.3(82.8-99.7) 0.349885 <![CDATA[CD8 / 4-1BB + ]]> 10.3(2.67-21.8) 3.8(0.26-11.6) 0.059625 <![CDATA[CD8 / CD27 + ]]> 24.2(9.64_44.4) 43.9(12.4-72.3) 0.008195 <![CDATA[CD8 / CD28 + ]]> 43.1(16.8-64.9) 70.5(34.6-95.2) 0.001735 <![CDATA[CD4 + LAG3 + ]]> 12(2.16-28.2) 6.3(0.24-19.4) 0.129779 <![CDATA[CD4 + PD1 + ]]> 44.4(12.9-81.5) 10.8(0.99-30.4) 0.001788 <h2 style=";text-align:left;direction:ltr"><![CDATA[CD4 <h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> TIM3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> ]]><h2 style=";text-align:left;direction:ltr"> 43(0.077-85.7) 56.7(17.8-85.5) 0.228513 <![CDATA[CD8 + LAG3 + ]]> 40.4(15.1-74.2) 30.5(6.03-51.2) 0.152748 <![CDATA[CD8 + PD1 + ]]> 31.7(7.9-60.2) 8.3(1.67-17.8) 0.005761 <h2 style=";text-align:left;direction:ltr"><![CDATA[CD8 <h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> TIM3<h2 style=";text-align:left;direction:ltr"> + <h2 style=";text-align:left;direction:ltr"> ]]><h2 style=";text-align:left;direction:ltr"> 46.7(1.48-93) 72.8(44.5-91.6) 0.028425

[1000] For example, using irradiated PBMC (irPBMC) + OKT3 mAb or the method of the invention (e.g., using T Cell TransAct TM ) Percentage of expanded REP TIL T cell subtypes determined by FACS analysis from nine donors. The mean percentage of each population is shown with ranges in parentheses. P values ​​were determined in Excel using paired t-tests (n=9).

[1001] T cell activation in response to αCD3 stimulation by TransAct REP vs. conventional REP

[1002] To compare the functionality of TILs expanded with the two REP methods, we examined changes in cell surface activation markers and cytokine secretion from harvested cells from REPTILs in response to αCD3 stimulation. Upon αCD3 stimulation with or without exogenous IL-2, TransAct REP TILs produced much higher levels of IFN-γ and granzyme B ( Figure 8 , Table 12). In the presence or absence of exogenous IL-2, CD4 + Population and CD8 + The average proportion of TILs expressing surface 4-1BB in the population was higher in TransAct REPTIL (Table 12).

[1003] These data show that TransAct REP supports better function of expanded TILs in response to T cell activation compared to conventional REP.

[1004] Table 12 CD4 after activation with anti-CD3 (oKT3) antibody in the presence or absence of exogenous IL-2 + or CD8 + 4-1BB in TIL + Summary of percentages

[1005]

[1006] *Data are shown as mean ± SD; P values ​​were determined by Student's paired t-test; n = 8.

[1007] In vitro MOS tumor killing effect of TILs from TransAct REP or conventional REP

[1008] Co-culture of TIL with autologous tumor-derived micro-organospheres (MOS) was performed to compare the tumor cell killing efficacy of conventional and TransAct REPTIL. REPTIL from donor T5101016 was co-cultured with autologous lung cancer MOS at different E:T ratios of 2:1, 3:1 or 4:1 (20,000-40,000 TIL: 10,000 cancer cells in MOS). Co-cultures were imaged every 2 hours until 68 hours and a gradual increase in caspase 3 / 7 signal was observed in the TIL group ( Fig. 9 ).

[1009] This assay confirmed the cytotoxicity of TIL against autologous NSCLCMs. TransActREPTIL (C-TIL051) showed significantly increased tumoricidal activity compared to conventional TIL at all tested E:T ratios, as indicated by caspase 3 / 7 signaling ( Fig. 9). These data show that TransAct REPTIL has better function in response to autologous tumor cells compared to conventional REPTIL.

[1010] TCR library of TransAct REPTIL vs. conventional REPTIL

[1011] Before (preparatory REP) and after REP amplification using conventional REP or TransAct REP, TCRβ chain sequencing data from TILs of 6 donors were compared with respect to TCR library diversity. Morisita index (which is a correlation analysis considering the number of clones and relative abundance between two samples) was displayed for each preparatory REP sample and REP sample pair. The value ranges from 0 to 1, and high values ​​indicate that the similarity between the overall libraries of the two samples is high. The Morisita index of TransAct REP is higher than that of conventional REP, indicating that TransActREP can generally retain the preparatory REP library to a higher degree (Table 13).

[1012] Table 13 Morisita index of REPTIL vs. prepared REPTIL from TCRβ chain sequencing data analysis

[1013] *STDEV, standard deviation.

[1014] In addition, composite analysis using different matrices from multiple aspects (including Simpson clonogenicity, TCR overlap between preparative REP ILs and TILs, and preservation of the first 100 preparative REP clones after REP) showed that the TransAct REP process was better than, or at least not inferior to, the conventional REP process in terms of preserving the preparative REP TCR library, which further supports the use of TransAct for the REP process.

[1015] Example 3: TILREP process development and TIL characterization

[1016] Our small-scale experiments using prepared REPTIL derived from tumors of 11 NSCLC patients demonstrated that commercially available αCD3 / αCD28 agonists can be used GMPTCell TransAct TM (abbreviated herein as TransAct) replaces irradiated feeder cells and αCD3 antibodies to support rapid expansion of TILs with the capacity to meet clinical dose requirements. The aim of this study was to develop a REP process for production-scale expansion of prepared REPTILs using TransAct. We also aimed to characterize TILs generated in process development (PD) runs and mock runs from a GMP facility with respect to T cell phenotype, repertoire diversity, and / or tumor killing function.

[1017] Our experimental data show that GMPTCell TransAct TM After activation, Cell culture devices or by sequential use and Xuri TM The W25 bioreactor successfully achieved REP of TIL at production scale. Characterization of TIL from process development runs demonstrated that the expanded cells showed favorable phenotypes and that the T cell receptor (TCR) repertoire representing the corresponding prepared REPTIL was fully retained. TIL also retained the ability to upregulate the expression of T cell activation surface markers and produce multiple cytokines in response to T cell activation signals. In addition, characterization of TIL products from simulated runs of our GMP facility demonstrated that the autologous cell therapy products we developed carried an early differentiation phenotype and obtained a strong tumor killing ability.

[1018] Material

[1019] Prepared REPIL derived from 11 donors were used for PD. Prepared REP cells from 5 donors (T5101001, T5101002, T5101005, T5101008, T5101010) were harvested before the preparation REP process optimization, and their CD3 + T cell percentages ranged from 38.7% to 98.0%; prepared REP cells from six other donors (T5101014, T5101015, T5101016, T5101017, T5101018, T5101024) were harvested after optimization of the prepared REP process, and their CD3 + T cell percentages ranged from 81.8% to 97.0%.

[1020] method

[1021] Use TransAct and use in sequence 10M and 100M device for REP

[1022] On day 0, the prepared REP cells were thawed in a water bath and washed twice with REP complete medium (CM, REP basal medium supplemented with 300, or 1000, 3000, or 6000 IU / mL IL-2). In one embodiment, the IL-2 concentration is 300 IU / mL. In another embodiment, the IL-2 concentration is 1000 IU / mL. In yet another embodiment, the IL-2 concentration is 3000 IU / mL. In yet another embodiment, the IL-2 concentration is 6000 IU / mL. The cells were then resuspended in REPCM and counted on an automated cell counter (NC-200). To initiate The culture in a 10M device will contain approximately 1×10 6 , 2×10 6 , 5×10 6 , 10×10 6 or 20×10 6 Aliquots of cell suspension of 10 viable cells and TransAct were added to the device at a volume ratio of TransAct: medium of approximately 1:150, 1:5, 1:10, or 1:17.5, and the final volume of the culture was adjusted to 10 mL, 15 mL, or 20 mL with REP CM. 10M at 37°C and 5% CO 2 incubator.

[1023] On day 3, 4, or 5, add pre-warmed REP CM to 10 M dilute the initial culture 10-fold, 20-fold, or 30-fold. Return the apparatus to CO 2 Incubator.

[1024] On day 6, 7, 8, 9, or 10, resuspend and count After the cells were grown for 10 M, the culture was transferred to a new 100M device and diluted 10-fold, 20-fold or 30-fold by adding pre-warmed REP CM. 100M in CO 2 incubator.

[1025] On the 12th, 13th, 14th, 15th, 16th, 17th, 18th, 19th, or 20th day, from G-

[1026] The cells were harvested at 100 μM. Aliquots of the remaining cells were pelleted and cryopreserved.

[1027] Use TransAct and use in sequence Installation and Xuri TM W25 for REP

[1028] On day 0, the prepared REP cells were thawed in a water bath and washed twice with REPCM. The cells were then resuspended in REPCM and counted on an NC-200. The culture in the 100M device will contain approximately 20×10 6 , 50×10 6 , 1000×10 6 or 200×10 6 Aliquots of cell suspension containing 10 viable cells and TransAct are added to the device at a volume ratio of TransAct: medium of approximately 1:150, 1:5, 1:10, or 1:17.5, and the final culture volume is adjusted to 50-100 mL with REPCM. Alternatively, if a closed system is used 100M-CS device, the barrel of a 50 ml syringe is connected to the Luer port of the medium addition line and then the G- Add the cell suspension and TransAct. Afterwards, heat seal the media addition line and remove the syringe barrel. 100M or 100M-CS placed in CO 2 incubator.

[1029] On day 3, 4, or 5, add pre-warmed REP CM to 100M dilute the initial culture 10-fold, 15-fold, or 20-fold. If using 100M-CS, with Add medium to the medium transfer bag containing REP CM welded to the medium addition line in the 100M-CS. After adding the medium, heat seal the line and remove the medium transfer bag. Device returns CO 2 Incubator.

[1030] At about day 6-10, about 25% or 50% of the spent medium is removed from Remove the top of the 100M and store in a new medium bottle. 100M-CS, remove the used medium through the medium addition / removal line and store in the medium transfer bag. Then resuspend the cells in The sample is placed in the device and taken for counting on the NC-200. Device returns CO 2 incubator until harvest.

[1031] To start Xuri TM REP, 2L or 10L Xuri TMCell bag mounted on Xuri TM The cells were then placed on a shaking tray of a W25 Cell Expansion System. Fresh CM was then added to the cells and the system was allowed to equilibrate for 2 hours.

[1032] According to the total number of cells, An aliquot of the cell suspension in the device is harvested into a transfer bag (for G-

[1033] 100M-CS, using GatheRex cell harvesting pump), so that the cell number meets the Xuri TM Cell seeding requirements. The transfer bag is then TM Connect the feed line of the cell transfer bag to transfer cells. The extra used medium (saved before cell counting) was added to the Xuri TM The volume of fresh CM in the cell bag will be half of the final volume of the total culture, and the final cell concentration will be approximately 0.5 x 10 6 / mL or 1×10 6 / mL or 2×10 6 / mL. Afterwards, start Xuri by shaking at a low speed and a small angle. TM Amplification.

[1034] Day 6, 7, or 8 and thereafter: Daily TM Samples were taken from the cell bag to count and monitor cell expansion and viability. Fresh REP CM was added after each cell count to adjust the culture to the desired cell concentration until the total culture volume reached 1 liter or 5 liters. Perfusion was then started the next day at 0.5 liters / day, 1 liter / day or 2 liters / day. The perfusion rate, along with the shaking speed and angle, was gradually increased daily according to the cell concentration.

[1035] In Xuri TM On the last day of culture, after taking samples for cell counting and FACS analysis, REP cells were harvested, washed and cryopreserved.

[1036] αCD3 stimulation

[1037] REP products from three donors (T5101015, T5101018, and T5101024) were thawed and placed in REP CM for 1 to 2 days. The cells were then washed and resuspended in REP basal medium without IL-2 or with 300 IU / mL IL-2 (final concentration), and 2×10 5 cells were seeded into one well of a 96-well plate. GMP CD3 pure (αCD3 antibody, OKT3) was diluted in the same medium and added to the wells at a final concentration of 1 μg / mL. Cells were stimulated overnight, and then supernatants were taken for cytokine analysis and cells were stained for FACS analysis. For each condition, the experiment was run in triplicate.

[1038] Cytokine analysis

[1039] To analyze cytokine concentrations in cell culture supernatants, LEGENDplex TM The Human CD8 / NK Assay Combo Kit is used to quantify multiple soluble analytes simultaneously. The assay was read on a CytoFLEX LX FACS instrument and analyzed using LEGENDplex TM Software to analyze data.

[1040] FACS

[1041] The cells were first treated with LIVE / DEAD TM Fixable Aqua staining was followed by staining with antibodies against various surface markers. The reagents were then passed through a CytoFLEX LX FACS instrument to acquire the samples. All data were analyzed using FlowJo V10 software.

[1042] Collect TIL culture medium samples

[1043] For the case where the cells reside at the bottom REP of the device, approximately 500 μL of supernatant was sampled at the indicated time points. TM REP of W25 bioreactor from Xuri TM The culture samples were collected at the sampling port of the cell bag and centrifuged at 400 g / min for 5 minutes. REP medium samples (200 μL-500 μL) were obtained by transferring the supernatant to a new 1.5-mL sterile tube. The medium samples were immediately stored in a -20°C refrigerator and thawed on ice at the time of analysis. IL-2 ELISA ELISA

[1044] Samples were diluted 15 to 300 times with REP basal medium according to IL-2 protein concentration. Samples were measured in duplicate or triplicate wells, and data were displayed as mean ± standard deviation (SD). The mean IL-2 concentration in three batches of fresh REP CM samples was designated as the day 0 concentration. Mass concentration was converted to unit concentration, provided that 1 ng / mL IL-2 was equivalent to 16.36 IU / mL.

[1045] Quantification of glucose and lactate concentrations in culture supernatants

[1046] Samples were aliquoted and analyzed using Glucose-Glo and Lactate-Glo assay kits following the manufacturer's recommended protocols. Culture supernatants were diluted 1:200 to 1:300 in PBS. Luminescence of the plates was read in SpectraMax iD3. Standard curves were generated in GraphPad Prism and sample values ​​were calculated in Excel.

[1047] TCR Repertoire Analysis

[1048] TCR β chains of TILs from two donors were sequenced to compare the Installation and Xuri TM TCR repertoire diversity before (pre-REP) and after full-scale REP expansion in a PD run in the W25 bioreactor (T5101015-3 and T5101024a).

[1049] Simulation run of TIL from GMP facility

[1050] Prepared REP TILs from 2 donors (T5101034 and T5101035) were expanded and cryopreserved in a GMP facility. For T5101034 and T5101035, the CD3 + The T cell percentages were 85.72% and 90.82%, respectively. The preparatory REP TILs were cryopreserved for 10 and 25 days, respectively, before initiating REP production in the same GMP facility. The REP standard operating procedures were developed based on the PD work and were applicable to both engineering runs and mock runs.

[1051] Characterization of TIL simulation run products

[1052] The yield of TIL mock run production was determined by automated cell counting on an NC-200 cytometer. TM The T cell phenotype of the products was analyzed by FACS on a clinical flow cytometry system. To determine nonspecific activation, the cryopreserved products were thawed and revived overnight, and then 1 × 10 5 Dynabeads TM Human T activator CD3 / CD28 (Thermo Fisher) was stimulated for 24 hours at a 1:1 ratio in a final volume of 200 μL. Cell supernatants were then harvested for IFN-γ ELISA using a commercial kit (Thermo Fisher). Alternatively, after overnight recovery, 2×10 5The cells were stimulated with αCD3 antibody (Miltenyi) at a final concentration of 1 μg / mL in a final volume of 200 μL for 24 hours. The cells were then harvested for FACS analysis of T cell activation markers including 4-1BB and OX40.

[1053] TIL simulation run products from 2 donors (T5101034 and T5101035) were also characterized by direct functional assays involving co-culture of TIL products with autologous tumor-derived micro-organospheres (MOS) (Ding et al., Patient-derived micro-organospheres enable clinical precision oncology, Cell Stem Cell, 2022, 29, 905-917, e906).

[1054] Results and Analysis

[1055] Use TransAct and use in sequence 10M and 100M device for C-TIL051PD operation

[1056] Use 10×10 6 Prepared REP TILs from 10 donors were treated with TransAct and G- 10M device and For the 100M device, we first implemented REP.

[1057] REP process conditions

[1058] REP of TILs requires adequate nutrients and high IL-2 concentrations, and the accumulation of metabolites such as lactate may inhibit T cell proliferation. We measured glucose levels, lactate levels, and IL-2 levels from culture supernatant samples before medium replacement / addition and at harvest. We found that IL-2 concentrations were high (>2000 IU / mL) at all time points in all samples tested, regardless of the cell proliferation rate ( Fig.10 , left). Glucose levels decreased during the first 6 days of culture as TILs began to expand; thereafter, media was added or exchanged, which maintained glucose levels to approximately 10 mM until the end of culture for most samples ( Fig.11 ), and we observed exponential expansion starting on day 6 ( Fig.10, right). Consistent with glucose consumption, lactate began to accumulate in the cultures during the first 6 days, after which it was diluted or maintained at similar low levels due to media addition / exchange. Overall, lactate levels in all samples tested remained well below 20 mM ( Fig.11 ), which according to previous studies is well tolerated by T cells 14 These data indicate that the feed scheme we developed is consistent with TIL expansion requirements in the device.

[1059] Use TransAct and use in sequence 10M and Amplification factor from PD operation at 100M device, Viability and T cell composition

[1060] After culture, TILs from 8 donors expanded at least 200-fold (Table 14), indicating successful REP. For these samples, we achieved an average expansion fold of 712.4 ± 292.2 (95% confidence interval (CI): 468.1 to 956.7) and high cell viability (97.95% ± 1.51%) and T cell purity, as measured by CD3 + The preparative REP yields of these samples showed a wide range (30 × 10 6 Up to 783×10 6 Since the yield of REP TILs was not significantly correlated with the REP yield, the yield of REP TILs did not seem to be correlated with the REP yield, and two samples (T5101002 and T5101008) with a REP yield of less than 50 million cells showed robust expansion using our protocol (Table 14). Given the high average expansion fold, the REP process developed in this paper is expected to expand as low as 10×10 6 Prepare REP TIL intermediates to achieve the target dose of the final REP product, i.e., 1×10 9 Up to 100×10 9 Notably, these 8 samples had greater than 80% of the CD3 + T cells (Table 14). In contrast, the other two CD3 + Preparatory REP samples with low T cell percentage (T5101005 and T5101010, CD3 + T cells (64.0% and 38.7%, respectively) showed poor expansion in the REP stage (17-fold and 167-fold, respectively). +The percentage of T cells may be important for TransAct-mediated REP. In conclusion, these data suggest that TransAct can indeed support the use of The device performed REP of NSCLC TILs at a production scale with a high success rate. The successful expansion of eight samples also demonstrated that the REP process using TransAct can be initiated immediately after thawing the REP-ready cells, without the need for 2 or more days of recovery that is typically required for conventional REP using irradiated feeder cells.

[1061] Table 14 Using TransAct and The expansion fold, viability and

[1062] T cell composition

[1063]

[1064] *Fold expansion of cells relative to the total number of starting cells; CD3 + (%), CD45 + CD3 in living cells + Percentage of cells; CD3 + CD8 + (%), CD3 + CD8 + The percentage of cells.

[1065] Use TransAct and use in sequence 10M and T cell phenotypes from PD runs at 100M device

[1066] FACS analysis showed that the 10M device and PD-run REPTIL of 100M device maintains relatively high CD8 + Cell percentage (average 47.19%±28.56%; Table 14). CD4 + TIL and CD8 + TILs expressed high levels of the dominant co-stimulatory molecule CD28 (means were 83.10% ± 30.07% and 66.03% ± 16.81%, respectively; Fig.12 and Table 15 ), and expressed CD27 to a lower extent (means were 26.46% ± 20.68% and 40.12% ± 21.15%, respectively; Fig.12 and Table 15). In terms of inhibitory markers, both groups showed low expression of PD-1 (means were 10.98% ± 12.60% and 9.26% ± 14.03%, respectively; Fig.12and Table 15 ) and LAG-3 (means were 7.46% ± 6.99% and 28.41% ± 19.40%, respectively; Fig.12 and Table 15 ), but highly expressed TIM-3 (means were 48.96% ± 20.70% and 61.04% ± 18.97%, respectively; Fig.12 Finally, REP TILs were mainly composed of central memory (T) cells that retain their proliferation capacity. CM ) cells and effector memory (T EM )Cellular composition( Fig.12 ). In CD4 + TIL and CD8 + TIL CM The average proportions of T were 51.88%±26.19% and 54.96%±13.82% respectively; and T EM The average proportions were 37.81%±23.11% and 29.31%±15.44% respectively (Table 1 6).

[1067] Table 15 Use Device uses TransAct to perform post-REP CD4 + TIL and CD8 + Selecting surface expression of activation and inhibitory markers on TILs

[1068]

[1069]

[1070] Table 16 in use Device uses TransAct to perform post-REP CD4 + TIL and CD8 + Memory phenotype of TILs.

[1071]

[1072] In summary, we use 10M device and The TransAct REP process developed by the 100M facility can be applied to manufacture TIL cell therapy products that meet cell dose requirements while maintaining favorable T cell phenotypes.

[1073] With TransAct and in turn using Installation and Xuri TM C-TIL051 PD for W25 Bioreactor run

[1074] The TransAct REP process is used in conjunction with 10M device and The 100M device process works well for donors with low REP yields. We have also developed a process for preparing REP TILs with high yields using G- 100M and Xuri TM TransAct REP process in the W25 bioreactor.

[1075] We performed 5 REP runs using prepared REP TILs from 3 donors. 100M or its closed system equivalent 100M-CS were inoculated with prepared REP TIL (range of cell number inoculated: 87×10 6 Up to 200×10 6 ), cells were activated with TransAct and The culture was then transferred to a 10 L Xuri TM The cell bag was further treated with Xuri TM W25 system amplification, except for T5101024, whose culture was aliquoted into two 10L Xuri TM Cell bags to compare different feeding regimens.

[1076] Culture conditions

[1077] exist During the installation and later at Xuri TM The expansion of TILs in the W25 bioreactor requires a different feeding protocol. (Day 7) and Xuri TM Glucose, lactate, and IL-2 levels were measured in the culture supernatant (daily). IL-2 concentrations were found to be high (>1000 IU / mL) at all time points in all samples tested, regardless of the cell proliferation rate ( Fig.13 ).

[1078] Glucose levels are also high ( Fig.14 ), while lactate was at low levels that were tolerated by most T cells, with the exception of T5101024aREP, which At the end of the culture period, a short period of high lactate levels ( Fig.14 ). For this REP, lactate levels were at Xuri due to the addition of fresh REP CM. TM decreased and remained at a low level during the culture period ( Fig.14 ), and we observed robust cell expansion ( Fig.15 ). These data indicate that the feed scheme we developed is consistent with Installation and Xuri TM TIL expansion requirements in both bioreactors.

[1079] With TransAct and in turn using Installation and Xuri TM W25 bioreactor from PD run TIL yield, viability and T cell composition

[1080] In 8 days to 12 days Xuri TM After amplification, the PD run had a minimum REP yield of 32.4 × 10 9 The yield reached 1×10 9 Up to 100×10 9 The target dose range (average yield 55.38±21.91×10 9 ; Fig.15 The final REP product also maintained high viability (average 98.42% ± 0.08%) and high CD3 + The average cell expansion fold of this REP process was 514.6 ± 206.2 (Table 17). It is worth noting that these cells retain the potential for further expansion because they have not reached their proliferation plateau when we terminated the process ( Fig.15 ), and can be found in Xuri TM The average cell expansion multiple is further increased by extending the culture time in the bioreactor. Similarly, for samples that proliferate rapidly and reach the target cell number early, the REP process can be stopped for harvesting. Therefore, the REP process provides flexibility in the future manufacturing time of TIL.

[1081] Table 17 Using TransAct and using Installation and Xuri TM W25 Bioreactor from REP

[1082] TIL yield, viability, and T cell composition of PD runs

[1083]

[1084] *Fold expansion of cells relative to the total number of starting cells at day 0. For T5101024a, only 1 / 2 Cultures used to establish Xuri TM Run, and by multiplying Phase and Xuri TM The total expansion fold was obtained by fold expansion of each stage. + (%), CD45 + CD3 in living cells + Percentage of cells; CD3+ CD8 + (%), total CD3 + CD8 + The percentage of cells.

[1085] With TransAct and in turn using Installation and Xuri TM TIL PD operation in W25 bioreactor T cell phenotype

[1086] We analyzed T cell phenotypes by FACS, which revealed that the REP products from the new process also maintained relatively high CD8 + Cell percentage (average 51.70% ± 25.40%; Table 17). CD4 + TIL and CD8 + TILs expressed high levels of CD28 (means were 77.14% ± 19.77% and 49.26% ± 26.18%, respectively) and moderate levels of TIM-3 (means were 31.72% ± 18.70% and 34.68% ± 31.40%, respectively), but low levels of 4-1BB, CD27, PD-1, and LAG-3 (the average positivity of these markers was around 10% or less; Fig.16 and Table 18). REP products are also mainly composed of T CM Cells and T EM cell( Fig.16 ) composed of, carrying and from only TILs generated by the device method have a similar favorable phenotype. + TIL and CD8 + TIL CM The average proportions of T were 40.16%±19.32% and 31.34%±19.88% respectively; and T EM The average proportions were 53.50%±21.66% and 48.86%±23.98%, respectively (Table 19).

[1087] Table 18 Using TransAct and sequentially Installation and Xuri TM CD4 after REP in W25 bioreactor + TIL and CD8 + Selecting surface expression of activation and inhibitory markers on TILs

[1088]

[1089] Table 19 Using TransAct and sequentially Installation and Xuri TM CD4 after REP in W25 bioreactor +TIL and CD8 + Memory phenotype of TILs

[1090]

[1091] In summary, we have determined that Xuri TM We used the following culture parameters to determine the best REP performance: Installation and Xuri TM The TransAct REP process developed in a bioreactor can be applied to manufacture TIL cell therapy products that can easily meet target cell doses while maintaining the desired T cell phenotype.

[1092] Characterization of TILs from PD runs by TCR sequencing

[1093] We performed TCRβ chain sequencing on TILs from 2 donors before (preparatory REP) and after manufacturing-scale REP PD runs to compare library diversity. REP TILs showed large TCR overlaps with their corresponding preparatory REP TILs (92% and 77% for T5101015-3 and T5101024a, respectively), suggesting that the TCR clones displayed by the preparatory REP TILs were mostly retained after the REP process. We also calculated the Morisita index for each preparatory REP sample and REP sample, which is a correlation analysis that considers the number and relative abundance of common clones between the two samples. Values ​​range from 0 to 1, and high values ​​suggest that the similarity between the overall libraries of the two samples is high. The Morisita index is also relatively high (0.80 and 0.54 for T5101015 and T5101024, respectively), which again shows that the REP TILs from the PD run can fully retain the library diversity of the preparatory REP TILs. This was further supported by additional analysis of the Simpson clonogenicity of the first 100 REP-prepared clones and after storage in REP.

[1094] Functional characterization of TILs from PD runs

[1095] To provide functional evidence for REP TILs from TILPD operation, we examined the expression of αCD3 in Xuri TM Cellular activation and cytokine secretion of TILs from 3 donors after REP. All 3 PD products were multifunctional, producing large amounts of IFN-γ, granzyme B, and TNF-α when stimulated with αCD3 alone, although absolute levels varied between donors. Cytokine production in some donors could potentially be enhanced by the addition of IL-2. αCD3 stimulation alone consistently upregulated CD4 + and CD8 +Surface expression of 4-1BB and OX40 in the population, the latter expression was significantly enhanced by the addition of IL-2. These data demonstrate that C-TIL051PD-run REP TIL retains functionality in response to T cell activation signals.

[1096] Characterizing TILs from simulation runs

[1097] Based on the PD work described above, we established standard operating procedures. T5101034 and T5101035 were run at full scale in a GMP facility. REP products were tested. Characterization of the TIL final product is shown below.

[1098] TIL yield, viability, and T cell composition from mock runs

[1099] At harvest, the REP yield from the mock run reached our target dose of 1 × 10 9 Up to 100×10 9 cells (for T5101034 and T5101035, respectively, 1.72×10 9 and 5.95×10 9 ; Table 20), with high viability (96.5% and 96.8% for T5101034 and T5101035, respectively; Table 20). For T5101034 and T5101035, the CD3 + The percentages were 86.98% and 97.42%, respectively, of which 30.96% and 9.81% were CD8 + T cells (Table 20).

[1100] Table 20 TIL yield, viability and T cell composition from mock runs

[1101] Sample ID Vitality(%) <![CDATA[CD3 + (%)]]> <![CDATA[CD3 + CD8 + (%)]]> Cell number T5101034 96.5 86.98 30.96 <![CDATA[1.72×10 9 ]]> T5101035 96.8 97.42 9.81 <![CDATA[5.95×10 9 ]]>

[1102] T cell phenotypes of C-TIL051 from mock runs

[1103] We examined T cell activation and exhaustion markers and memory phenotypes of REP TIL products from mock runs. + Among the subpopulations, 4-1BB surface expression was minimal in both samples (0.20% and 0.87% for T5101034 and T5101035, respectively), whereas PD-1 surface expression was repeatedly detected (14.56% and 26.90% for T5101034 and T5101035, respectively; Table 21). + In subpopulations, such as compared with CD4 +In the subgroups, 4-1BB surface expression was slightly higher (2.36% and 6.13% for T5101034 and T5101035, respectively), while PD-1 surface expression was lower in both samples (about 5%) (Table 21). In addition, phenotypic analysis showed that the two TIL products were mainly composed of memory cells, with T5101034 and T5101035, respectively, in naive or stem cell memory (T N / T SCM ) stage were 19.93% and 22.35% respectively, and in the central memory (TC M ) stage were 29.15% and 19.72% respectively, and in the effect memory (T EM ) stage were 37.56% and 34.37% respectively (Table 22). EFF ) ratios were 13.36% and 23.56% respectively (Table 22).

[1104] Table 21 CD4 from simulation runs + TIL and CD8 + Surface expression of 4-1BB and PD-1 on TILs

[1105]

[1106] Table 22 Memory phenotypes of TILs from simulation runs

[1107]

[1108] Functional characterization of TILs from simulation runs

[1109] We first performed IFN-γ release analysis for functional characterization of REP TIL products. After overnight stimulation with anti-CD3 / CD28-coupled Dyna beads, both products released a large amount of IFN-γ (10.46 fg / cell and 16.15 fg / cell for T5101034 and T5101035, respectively; Fig.17 ).

[1110] We also examined the surface expression of T cell activation markers in REP TIL products after overnight stimulation with αCD3 antibody. Activation signals strongly induced 4-1BB and OX40 in the CD4 + Surface expression in CD8+ subsets or CD8+ subsets ( Fig.18 ).

[1111] In addition, we evaluated the in vitro tumoricidal effects of REP TILs from two full-scale mock runs on MOS generated from the corresponding tumor specimens. T5101034 and T5101035 MOS were confirmed to be of tumor origin based on morphology, immunohistochemical staining for EpCAM, and immunofluorescent staining for EpCAM and pan-cytokeratin. In subsequent potency analyses, REP TILs were used at higher effector / target ratios (5:1 and 10:1, Fig.19 ) co-cultured, both products were able to eradicate MOS, which was quantified by measuring the fluorescence intensity from the remaining NIR680 dye-positive live tumor cells. In both cases, this effect could be detected as early as 8 hours of co-culture and became increasingly evident over time ( Fig.19 Importantly, the addition of HLA class I blocking antibodies during co-culture completely abolished the killing effect of T5101034 TIL products, while HLA class II blocking was ineffective ( Fig. 20 , left), suggesting that the killing function is mainly mediated by CD8 + T cell mediated. In the case of T5101035, the addition of HLA class I or II blocking antibodies abolished the killing effect ( Fig. 20 , right), suggesting that CD4 is required for the killing function + Although the donors were different, the dependence of HLA recognition in both cases indicated that the tumor killing function of T5101034TIL and T5101035TIL was tumor cell specific.

[1112] In addition, we collected the culture supernatant of TIL and MOS co-culture (E:T=5:1) on day 3 for cytokine analysis. Compared with the TIL only control, the TIL and MOS co-culture group had significantly increased levels of IFN-γ and granzyme A in the culture supernatant ( Fig.21 ). The level of granzyme B in the supernatant of T5101034TIL and MOS co-culture was also increased, and the level of TNF-α in the supernatant of T5101035TIL and MOS co-culture was also increased ( Fig.21 ). These results are consistent with the previously described results on the tumor killing potency of TILs. In addition, the addition of HLA-1 class blocking antibodies significantly reduced the cytokine levels in the co-culture supernatants of TILs and MOSs from both donors, while the addition of HLA-II class blocking antibodies mainly reduced the cytokine levels in the co-culture supernatants of T5101035 TILs and MOSs ( Fig.21 ). Despite the different donors, the dependence of HLA recognition in both cases indicates that the tumor killing function of TIL occurs via TCR. In summary, these data indicate that TIL from the simulated run kills autologous tumor cells with high potency.

[1113] in conclusion

[1114] We have successfully developed a feeder-free TIL REP process using αCD3 / αCD28 nanoparticles. This TIL REP process can be initiated immediately after thawing the prepared REP cells. Depending on the viable cell count of the prepared REP TILs, different cell expansion devices or systems (i.e., 10M, 100M-CS and Xuri TM W25 bioreactor) can be used for REP process and can achieve the target therapeutic dose. T cell pool diversity is retained in TIL. TIL also shows the desired T cell phenotype, the ability to upregulate T cell activation markers and produce multiple cytokines in response to T cell activation signals. In addition, functional characterization of TIL from simulated runs shows that the product strongly kills autologous tumor cells.

[1115] The scope of the present invention is not limited by the specific shown and described above. Those skilled in the art will recognize that there are suitable alternatives to the materials, layouts, constructions and scale examples shown. Various references, including patents and various publications, are cited and discussed in the description of the present invention. The citation and discussion of such references are provided only to illustrate the description of the present invention and are not to admit that any reference is the prior art relative to the invention described herein. All references cited and discussed in this specification are fully incorporated herein by reference. Those skilled in the art will think of the variations, modifications and other embodiments described herein without departing from the spirit and scope of the present invention. Although certain embodiments of the present invention have been shown and described, it will be apparent to those skilled in the art that changes and modifications can be made without departing from the spirit and scope of the present invention. The subject matter described in the above description is provided only by way of illustration and not as a limitation.

Claims

1. A method for amplifying tumor infiltrating lymphocytes (TIL), the method comprising: (a) culturing a first cell population in a first cell culture medium to generate a second cell population, wherein the first cell population is obtained from a tumor sample from a patient; and (b) contacting the second cell population with a polymer matrix comprising an anti-CD3 antibody and an anti-CD28 antibody or fragments thereof in a second cell culture medium to generate a third cell population, wherein the second cell culture medium comprises about 100 IU / mL to about 8000 IU / mL interleukin-2 (IL-2).

2. The method of claim 1, wherein the first cell culture medium comprises about 2000 IU / mL to about 8000 IU / mL IL-2.

3. The method of claim 1, wherein in step (a) the first cell population is cultured for about 10 days to about 40 days.

4. The method of claim 3, wherein in step (a) the first cell population is cultured for about 10 days to about 14 days.

5. The method of claim 1, wherein the second cell culture medium comprises about 500 IU / mL to about 4000 IU / mL IL-2.

6. The method of claim 5, wherein the second cell culture medium comprises about 3000 IU / mL IL-2.

7. The method of claim 1, further comprising cryopreserving the second cell population after step (a).

8. The method of claim 1, wherein in step (b) the contacting is from about 3 days to about 17 days.

9. The method of claim 1, wherein the third cell population is at least 100 times greater in number than the second cell population.

10. The method of claim 9, wherein the third cell population is about 100-fold to about 2000-fold greater in number than the second cell population.

11. The method of claim 1, wherein the tumor sample is from a solid tumor.

12. The method of claim 11, wherein the solid tumor comprises a sarcoma, hepatocellular carcinoma, glioma, head and neck cancer, bone cancer, brain cancer, breast cancer, anal cancer, anal canal cancer, anorectal cancer, eye cancer, intrahepatic bile duct cancer, joint cancer, cervical cancer, pleural cancer, nasal cancer, nasal cavity cancer, middle ear cancer, oral cancer, vulvar cancer, colon cancer, esophageal cancer, cervical cancer, gastrointestinal cancer, hypopharyngeal cancer, laryngeal cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, peritoneal cancer, omental cancer, mesenteric cancer, pharyngeal cancer, prostate cancer, rectal cancer, kidney cancer, small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, ureter cancer, bladder cancer, or a combination thereof.

13. Tumor infiltrating lymphocytes obtained by the method of claim 1.

14. A cell population enriched for tumor-infiltrating lymphocytes or expanded from tumor-infiltrating lymphocytes, comprising one or more of the following: (i) Percentage of CD3 + About 3% to about 88% of cells are CD3 + CD8 + T cells, (ii) Percentage of CD3 + About 10% to about 96% of cells are CD3 + CD4 + T cells, (iii) Percentage of CD4 + Cells from about 50% to about 88% CD4 + T CM T cells, (iv) Percentage of CD8 + Cells from about 28% to about 82% CD8 + T CM T cells, (v) Percentage of CD4 + Cells from about 11% to about 49% CD4 + T EM T cells, and (vi) Percentage of CD8 + Cells from about 11% to about 61% CD8 + T EM T cells, wherein the cell population comprises no less than 70% viable cells, and wherein the cell population is generated from a tumor sample from a patient.

15. The cell population according to claim 14, wherein the cell population comprises no less than 80% of CD3 + T cells.

16. The cell population according to claim 14, wherein the cell population comprises a percentage of CD4 + Cells from about 10% to about 51% CD4 + CD27 + T cells.

17. The cell population according to claim 14, wherein the cell population comprises a percentage of CD8 + Cells from about 12% to about 72% CD8 + CD27 + T cells.

18. The cell population according to claim 14, wherein the cell population comprises a percentage of CD8 + Cells are approximately 34% to approximately 95% CD8 + CD28 + T cells.

19. The cell population according to claim 14, wherein the cell population comprises a percentage of CD4 + Cells from about 82% to about 100% CD4 + CD28 + T cells.

20. The cell population according to claim 14, comprising a percentage of CD4 + About 0.2% to about 5.8% of cells are CD4 + 4-1BB + T cells.

21. The cell population according to claim 14, wherein the cell population comprises a percentage of CD8 + About 0.2% to about 11.6% of cells are CD8 + 4-1BB + T cells.

22. The cell population according to claim 14, comprising a percentage of CD4 + Cells from about 0.2% to about 19.5% CD4 + LAG3 + T cells.

23. The cell population according to claim 14, wherein the cell population comprises a percentage of CD8 + Cells from about 6% to about 51.2% CD8 + LAG3 + T cells.

24. The cell population according to claim 14, comprising a percentage of CD4 + Cells from about 0.9% to about 31% CD4 + PD1 + T cells.

25. The cell population according to claim 14, wherein the cell population comprises a percentage of CD8 + About 1% to about 18% of cells are CD8 + PD1 + T cells.

26. The cell population of claim 14, comprising no more than 10% CD56 + NK cells.

27. The cell population of claim 14, generated by a method of expanding tumor infiltrating lymphocytes (TILs), the method comprising: (a) culturing a first cell population in a first cell culture medium to generate a second cell population, wherein the first cell population is obtained from a tumor sample from a patient; and (b) contacting the second cell population with a polymer matrix comprising an anti-CD3 antibody and an anti-CD28 antibody or fragments thereof in a second cell culture medium, wherein the second cell culture medium comprises about 100 IU / mL to about 8000 IU / mL interleukin-2 (IL-2).

28. A method for expanding a cell population enriched for tumor infiltrating lymphocytes, the method comprising: (a) culturing cells obtained from a tumor sample of a patient; (b) treating the cultured cells to generate a cell population enriched for tumor-infiltrating lymphocytes, the cell population comprising one or more of the following: (i) Percentage of CD3 + About 3% to about 88% of cells are CD3 + CD8 + T cells, (ii) Percentage of CD3 + About 10% to about 96% of cells are CD3 + CD4 + T cells, (iii) Percentage of CD4 + Cells from about 50% to about 88% CD4 + CD45RA_CD62L+ central memory T cells, (iv) Percentage of CD8 + Cells from about 28% to about 82% CD8 + CD45RA-CD62L+ central memory T cells, (v) Percentage of CD4 + Cells from about 11% to about 49% CD4 + CD45RA_CD62L- effector memory T cells, and (vi) Percentage of CD8 + Cells from about 11% to about 61% CD8 + T CD45RA_CD62L- effector memory T cells.

29. A cell population enriched for tumor-infiltrating lymphocytes, obtained by the method of claim 28.

30. A method of treating a patient with cancer, the method comprising administering to the patient the tumor infiltrating lymphocytes of claim 13.

31. The method of claim 30, wherein about 1×10 9 to about 1×10 11 cells.

32. The method of claim 30, wherein about 5×10 9 About 9×10 10 cells.

33. The method of claim 30, wherein the cancer is melanoma, cervical cancer, lung cancer, colorectal cancer, breast cancer, or head and neck cancer.

34. A method of treating a patient with cancer, the method comprising administering to the patient the cell population of claim 14.

35. A method of treating a patient with cancer, the method comprising administering to the patient the cell population of claim 29.

36. The method of claim 34, wherein the cancer is melanoma, cervical cancer, lung cancer, colorectal cancer, breast cancer, or head and neck cancer.

37. The method of claim 35, wherein the cancer is melanoma, cervical cancer, lung cancer, colorectal cancer, breast cancer, or head and neck cancer.

38. The method of claim 30, wherein the cancer comprises sarcoma, hepatocellular carcinoma, glioma, head and neck cancer, bone cancer, brain cancer, breast cancer, anal cancer, anal canal cancer, anorectal cancer, eye cancer, intrahepatic bile duct cancer, joint cancer, cervical cancer, pleural cancer, nasal cancer, nasal cavity cancer, middle ear cancer, oral cancer, vulvar cancer, colon cancer, esophageal cancer, cervical cancer, gastrointestinal cancer, hypopharyngeal cancer, laryngeal cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, peritoneal cancer, omental cancer, mesenteric cancer, pharyngeal cancer, prostate cancer, rectal cancer, kidney cancer, small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, ureter cancer, bladder cancer, or a combination thereof.

Citation Information

Patent Citations

  • Method for polyclonal stimulation of T cells by flexible nanomatrices

    US10513687B2

  • Solubilization of proteins for pharmaceutical compositions using polymer conjugation

    US4766106A

  • Preparation of a polymer / interleukin-2 conjugate

    US4902502A

  • Methods and compositions for enhanced delivery of bioactive molecules

    US6706289B2